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IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma
T Miyagaki, M Sugaya, H Suga, M Kamata, H Ohmatsu, H Fujita, Y Asano, Y Tada, T Kadono and
S Sato Department of Dermatology, University of Tokyo, Tokyo, Japan
Both patients with cutaneous T-cell lymphoma (CTCL) and those with atopic dermatitis (AD) have
pruritus, Th2-biased T cells, and a tendency to have bacterial infections, suggesting a common patho-
logic basis for these two diseases. Recently, IL-22-producing T cells were reported in skin of AD
patients. In this study, we investigated expression levels of Th22 and Th17-related molecules in
lesional skin and sera isolated from patients with CTCL. IL-22, IL-10, IL-4, CCL20, and CCR6
mRNA levels, but not IL-17A, IL-17F, IL-23p19, IL-8, or IL-20, were significantly elevated in lesional
skin of CTCL. In the lesional skin of CTCL, mRNA levels of IL-22, CCL20, and CCR6 significantly
correlated with one another. Immunohistochemistry revealed that IL-22-producing cells and CCR6+
cells infiltrated in the dermis and that epidermal keratinocytes expressed CCL20 and pSTAT3 in
CTCL skin. Serum IL-22 levels in CTCL patients were 40.1 ± 50.4 pg/ml, which were significantly
higher than healthy controls (14.1 ± 3.2 pg/ml; P<0.01). Serum CCL20 levels of patients with CTCL
were 169.1 ± 440.5 pg/ml, which were significantly higher than healthy controls (12.5 ± 10.9 pg/ml;
P<0.01). Serum IL-22 levels correlated with serum LDH, sIL-2R, and CCL27 levels, all of which were
reported to be disease severity markers of CTCL (r=0.32, P<0.05, r=0.35, P<0.05, and r=0.38,
P<0.05, respectively). Serum CCL20 levels correlated with serum LDH levels (r=0.30, P<0.05).
Our results suggest that IL-22 is important in establishing the tumor microenvironment for CTCL.
Enhanced expression of CCL20 may explain epidermal hyperplasia and migration of CCR6+ cells,
such as Langerhans cells, into lesional skin. Relatively low expression of IL-17 may explain the lack
of neutrophils in lesions of CTCL, which correlates with bacterial infections that commonly occur
in skin affected by CTCL.
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Primary cutaneous B cell lymphomas: A review of clinicopathological presentation, charac-
terization of prognostic markers, treatment, and outcome
F Kartono,1 HK Wong1 and P Porcu2 1 Dermatology, The Ohio State University, Columbus, OH
and 2 Hematology/Oncology, The Ohio State University, Columbus, OH
Primary cutaneous B-cell lymphomas (PCBCL) comprise approximately 25% of all cutaneous lym-
phomas. Although some B cell lymphomas have an indolent course, a subset of patients with this
disease experience an aggressive course. The current challenge lies in correctly utilizing staging
tools, serological markers, and prognostic indicators to distinguish the different subtypes of PCBCL.
We performed a restrospective review in a series of patients presenting with PCBCL at the Ohio State
University Cutaneous Lymphoma Center between 1998 and 2011. The aims of this study were to:
1) assess the significance and practicality of the current WHO-EORTC and TNM classification of
PCBCL, 2) define more precisely the clinicopathologic features, current accepted and novel prog-
nostic markers in patients with PCBCL, 3) analyze the practiced staging protocol and treatment
options for patients with PCBCL, and 4) correlate the staging, workup, and treatment data in this
study with disease survival. The lymphoma database was searched and clinical records were reviewed.
The majority of patients were treated with radiotherapy for localized disease, with chemotherapy
given in 10% of patients, and rituximab given in 13% of patients. Surgical excision as the sole modal-
ity of treatment was adequate in 21% of patients. Overall survival and disease-free survival was
assessed at 1,2, and 5 years and correlation was assessed for age, leg lesions, locoregional nodal
involvement, and for those treated with chemotherapy. Expression of CD5, bcl2, bcl6, and MUM-
1were analyzed for a correlation with prognosis. On serology, high serum levels of beta-2- microglob-
ulin correlated with patients with a diagnosis of PCLBCL-leg type, of which one died from the dis-
ease. The experience with PCBCL in our institution emphasizes the challenging diagnosis, staging,
and therapeutics of these rare diseases and suggests further studies be conducted to prevent overtreat-
ment of certain subgroups of PCBCL patients.
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IRF8 controls activation-induced cell death on CD8 T cells by regulating Bcl2
F Miyagawa, Y Tagaya, K Ozato and SI Katz NIH, Bethesda, MD
We previously reported that interferon regulatory factor 8 (IRF8) regulates effector differentiation of
CD8 T cells using IRF8KO mice. However, when IRF8 is overexpressed, it induces cell death in CD8
T cells, suggesting that IRF8 may have dual functions. To determine how IRF8 exhibits these dual
functions IRF8 was constitutively expressed by retroviral transduction of CD8OT-I cells and adop-
tively transferred into K14-sOVA transgenic (Tg) mice. Mock-transduced OT-I cells induced rapid
weight loss and caused death in 5-7 days when injected into Tg mice. In contrast, mice injected
with IRF8-transduced OT-I cells survived. Consistent with this, the percentage of injected OT-I cells
in skin-draining LN and spleen was lower in Tg mice transferred with IRF8-OT-I cells compared with
those with mock-OT-I cells. In vitro experiments showed that mock-OT-I cells proliferated to a greater
extent than did IRF8-OT-I cells when cultured with IL-2. BrdU incorporation by live cells was sim-
ilar between mock-OT-I cells and IRF8-OT-I cells. However, Annexin V staining showed that 44.5%
of IRF8-OT-I cells were positive for Annexin V, while 10.5% of mock-OT-I cells were positive, sug-
gesting that growth impairment of IRF8-OT-I cells may be caused by acceleration in cell death, not
by defects in proliferation. We found by western blot that IRF8-OT-I cells had reduced Bcl2 expres-
sion levels compared to mock-OT-I cells. Real-time PCR showed that mRNA expression of Bcl2
was not significantly altered between mock- and IRF8-OT-I cells. These data suggest that IRF8
might control Bcl2 activity through modulation of translation or protein stability rather than by
transcription. However, the presence of a proteasome inhibitor did not restore Bcl2 expression in
IRF8-OT-I cells, suggesting that IRF8 does not control Bcl2 through accelerating protein degrada-
tion. Finally, pulse-chase studies using [35S] methionine demonstrated that IRF8 inhibited Bcl2 pro-
tein synthesis. Together, these results suggest that IRF8 regulates apoptosis by inhibiting Bcl2 pro-
tein synthesis and may regulate the contraction phase of CD8 T cells immune responses.
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Enhanced NGFR signal in melanoma cells suppresses the tumor recognition by melanoma
specific T cells
T Inozume,1 J Furuta,1 K Hanada2 and S Shimada1 1 Dermatology, University of Yamanashi,
Yamanashi, Japan and 2 Surgery Branch, National Cancer Institute, Bethesda, MD
IFN-γ released from CTLs in effector phase is essential to reject the bulky melanoma tumors. On the
other hands, IFN-γ is known to induce some immunosuppressive factors in tumor cells such as PD-
L1. However, most of the immunosuppressive factors induced by IFN-γ other than PD-L1 are still
unknown. In this study, we demonstrated that some melanoma cell lines become less sensitive to
CTL recognition when they are treated with IFN-g before exposure to CTLs. By DNA microarray
analysis, we compared gene expression profiles of such resistant cell lines with cell lines that are
susceptible in CTL assay, and identified candidates of immunosuppressive factors induced by IFN-
γ in melanoma. NGFR is one of the candidate genes. Recently, NGFR is identified as a marker of
cancer stem cell like population in human melanoma tissues (Nature, 2010). We demonstrated that
melanoma cells retrovirally transduced with NGFR and its ligand were less sensitive to recognition
by melanoma specific CTLs assessed by in vitro cytokine release. Moreover, we found that expres-
sion level of PD-L1 on melanoma cells correlated with expression level of NGFR, and NGFR and
PD-L1 over-expressed on melanoma cells synergistically suppressed the tumor recognition by
melanoma specific T cells in vitro. Also we found that one possible mechanism of the suppression
was increased production of immunosuppressive factors from melanoma cells mediated by enhanced
NGFR signal. This is the first report showing the impact of NGFR on tumor immunity, and our
observation suggests that NGFR should be targeted for enhancing anti-tumor immunoresponse.
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Cancer exome analysis reveals a T cell dependent mechanism of cancer immunoediting
MD Vesely,1 H Matsushita,1 DC Koboldt,2 CG Rickert,1 ER Mardis2,3 and RD Schreiber1 1
Department of Pathology and Immunology, Washington University in St. Louis, Saint Louis,
MO, 2 The Genome Institute, Washington University in St. Louis, Saint Louis, MO and 3
Department of Genetics, Washington University in St. Louis, Saint Louis, MO
Cancer immunoediting, the process whereby the immune system controls tumor outgrowth and
shapes tumor immunogenicity, is comprised of three phases: elimination, equilibrium and escape.
Although many immune components that participate in this process are known, its underlying mech-
anisms remain poorly defined. A central tenet of cancer immunoediting is that antigens expressed
in tumor cells can be recognized by T cells and thus drive immunologic destruction or sculpting of
a developing cancer. Our current understanding of tumor antigens comes almost entirely from analy-
ses of tumor cells that develop in immunocompetent hosts and thus most likely have been subjected
to cancer immunoediting. Little is known about the antigens expressed in nascent tumor cells,
whether they are sufficient to induce host-protective, anti-tumor immune responses or whether their
expression is modulated by the immune system. Here, using massively parallel sequencing and class
I prediction algorithms, we characterize expressed mutations in highly immunogenic methyl-
cholanthrene-induced sarcomas derived from immunodeficient Rag2-/- mice which phenotypically
resemble nascent primary tumor cells. Using this information, we identify mutant spectrin-β2 as a
potential major rejection antigen of the d42m1 sarcoma and validate this prediction by conven-
tional antigen expression cloning and detection. We also demonstrate that editing of d42m1 occurs
via a T cell-dependent immunoselection process that promotes outgrowth of pre-existing variants
lacking mutant spectrin-β2 within the tumor cell population. These results demonstrate that the
strongly immunogenic characteristic of an unedited tumor can be ascribed to expression of a highly
antigenic mutant protein and show that formation of antigen-loss variants via T cell-dependent
immunoselection represents one mechanism of cancer immunoediting.
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Noncalcemic natural vitamin D analog, 20(OH)D3, enhances immunosuppressive proper-
ties of an altered peptide ligand
LK Myers,1 AE Postlethwaite,1,2 W Li,3 DD Miller,3 RC Tuckey4 and A Slominski5 1 Rheumatology,
University of Tennessee Health Sciences Center (UTHSC), Memphis, TN, 2 Research,
Veterans Affairs Medical Center, Memphis, TN, 3 Pharmaceutical Sciences, UTHSC, Memphis,
TN, 4 Biomedical, Biomolecular and Chemical Sciences, University of Western Australia,
Crawley, WA, Australia and 5 Pathology, UTHSC, Memphis, TN
The purpose of this study was to determine whether 20(OH)D3 enhances immunosuppressive prop-
erties of an altered peptide ligand (APL). APL peptides differ in amino acid sequence from the par-
ent T cell antigen epitope peptide at contact points with the T cell receptor. APLs suppress autoim-
mune models in mice and (to a variable extent) certain human autoimmune diseases. Our group
has been studying immunomodulatory properties of novel noncalcemic vitamin D analogs such as
20(OH)D3 and report 20(OH)D3 potentiates immunosuppressive properties of an APL. An APL
patterned after the immunodominant epitope of type II collagen (CII) (i.e., A9), CII 245-270 (A260,
B261, N263), and/or 20(OH)D3 or vehicle was administered at suboptimal dosage to DBA/1 mice
immunized with CII to induce arthritis. Arthritis was significantly less in mice treated with the com-
bination of APL-A9 + 20(OH)D3 than in mice treated with either alone. Lymph node cells (LNC)
stimulated with murine CII epitope peptide (i.e., A2) from these APL-A9 + 20(OH)D3 treated mice
demonstrated greater enhanced production of IL-10 and greater suppression of IFNγ production
than LNC from either APL-A9 or 20(OH)D3 treated mice. Surprisingly, APL-A9 (but not A2), when
added to T cell cultures from CII transgenic mice, upregulated expression of the vitamin D recep-
tor (VDR). In conclusion, we present compelling evidence that the combination of 20(OH)D3 +
APL-A9 is more effective than either alone in suppressing immune arthritis, upregulating IL-10 secre-
tion, or suppressing IFNγ secretion. It is intriguing that APL-A9 might enhance the immunomodu-
latory effect of 20(OH)D3 by increasing VDR expression, raising the possibility that 20(OH)D3 might
be an adjunctive therapy with APL platform peptides to treat autoimmune diseases.
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Proteomic analysis of psoriatic skin tissue for identification of differentially expressed pro-
teins: Up-regulation of GSTP1, SFN, and PRDX2 in psoriatic skins
J Cho, J Kweon and K Lee Department of Dermatology, Keimyung University School of
Medicine, Daegu, Republic of Korea
Psoriasis is a chronic inflammatory skin disease, characterized by a combination of abnormal pro-
liferation of keratinocytes, immunology, and vascular proliferations. Proteomics have revealed some
clues regarding pathogenesis of psoriasis. In the present study, we conducted an investigation of
different proteomes of psoriatic lesional skin, which is compared with normal and nonlesional pso-
riatic skin. We performed 2-D gel electrophoresis, LC-MS/MS analysis, and database searches. Expres-
sion of proteins was evaluated by immunoblot and immunohistochemistry analysis. Our proteome
data showed differential expression of 74 and 145 protein spots in non-lesional and lesional pso-
riatic skin, respectively. Eleven of 36 proteins, which were identified by LC-MS/MS, were catego-
rized as apoptosis regulating proteins. Other protein spots were categorized as proteins with involve-
ment in negative regulation of apoptosis, defense response-related proteins, and inflammatory
response. Of particular interest, increased expression of GSTP1 and PRDX2, which are involved in
the Redox balance system, and SFN, which is involved in the cellular proliferation system, was
observed in psoriatic lesional skin. Localization of GSTP1 and SFN was observed above the mid-
dle layer of epidermis in psoriatic skin lesions. Expression of PRDX2 was clearly observed below
the middle layer of epidermis in chronic type psoriatic skin lesions. Taken together, 36 identified
proteins were associated with biological regulation, including regulation of cell death, defense
response, inflammatory response, and ROS regulation. PRDX-2 and GSTP-1 may play roles in
compensating mechanisms for reduction of ROS stress, and SFN may play roles in prevention of
cancer development in proliferating cells through G2/M cell cycle arrest upon accidental DNA dam-
age within psoriatic skin lesions.
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Modulation of lymph node cell cytokine production by intradermal administration of calci-
tonin gene-related peptide (CGRP)
W Ding,1 M Manni,1 J Lee,1 JA Wagner2 and RD Granstein1 1 Dermatology, Weill Cornell
Medical College, New York, NY and 2 Neurology and Neuroscience, Weill Cornell Medical
College, New York, NY
CGRP has immunomodulatory effects in vitro on both antigen presenting cells and T lymphocytes.
Immunization of mice at sites injected intradermally with CGRP leads to decreased induction of
contact hypersensitivity to the hapten dinitrofluorobenezene (DNFB). To further understand the in
vivo effects of CGRP, groups of mice were injected intradermally on the mid-dorsum with 530
pmol of CGRP or medium alone. Fifteen minutes after each injection, 20 μl of 1% DNFB in ace-
tone/olive oil (3:1) was applied epicutaneously at the injected site. Three days later, all mice were
sacrificed, draining lymph nodes were removed and a single-cell suspension of lymphocytes pre-
pared. Lymphocytes were stimulated by plating them on plates coated with anti-CD3 monoclonal
antibody (mAb) in the presence of anti-CD28 mAb. Forty-eight hours later, supernatants were har-
vested and examined for cytokine content by ELISA. CGRP significantly suppressed production of
interleukin (IL)-9, IL-22 and interferon-γ (IFNγ) while significantly augmenting production of IL-4
and IL-17A. Although statistically significant, the increase in IL-17A was less pronounced than the
other changes observed. These results support the concept that CGRP is an endogenous immune
regulator within the skin. The finding that IL-9 induction is significantly suppressed is in accord
with unpublished findings from our laboratory that exposure of Langerhans cells to CGRP suppresses
the IL-9 response to Langerhans cell antigen presentation to responsive T cells. Additionally, the
finding that lymph node cell production of IL-17A is enhanced is of particular interest as CGRP has
been shown to be involved in the pathophysiology of psoriasiform dermatitis observed in the KC-
Tie2 murine model of psoriasiform dermatitis. These findings support the concept that CGRP is an
endogenous regulator of cutaneous immunity.
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Exposure of Langerhans cells to calcitonin gene-related peptide (CGRP) biases antigen pres-
entation away from an interleukin (IL)-9 response
W Ding,1 LL Stohl,1 M Manni,1 JA Wagner2 and RD Granstein1 1 Dermatology, Weill Cornell
Medical College, New York, NY and 2 Neurology and Neurosciences, Weill Cornell Medical
College, New York, NY
IL-9 is recognized as an important regulatory cytokine for allergic phenomena and may play a role
in atopic dermatitis. In order to examine a possible role for CGRP in regulating antigen presenta-
tion for an IL-9 response, BALB/c Langerhans cells were exposed to 100 nM CGRP for 2 hours fol-
lowed by washing 4 times and addition of 2 x 105 T cells from DO11.10 transgenic mice. A frag-
ment of chicken ovalbumin (cOVA323-339) was then added to wells to a concentration of 10 μM.
DO11.10 mice express transgenes in the alpha and beta chains of their T cell receptors such that
they respond spontaneously to cOVA323-339. After 48 hours, supernatants were harvested and assessed
by ELISA for IL-9 content. CGRP dose-dependently inhibited the IL-9 response to antigen presen-
tation in this assay. This effect of CGRP could be blocked by the presence of the CGRP receptor 1
inhibitor CGRP8-37. These findings suggest that CGRP may have an important modulatory role in the
expression of allergic phenomena and, perhaps, atopic dermatitis. Additionally, previous work from
our laboratory has shown that CGRP treatment of Langerhans cells results in enhancement of the
IL-4 response by responsive DO11.10 cells and Th2 hybridomas. The divergent regulation of the IL-
4 and IL-9 responses by CGRP treatment of Langerhans cells is of particular interest as IL-9 has
been considered to be a Th2 cytokine. More recently, a distinct subset of T helper cells capable of
producing IL-9 (Th9 cells) has been identified. These findings suggest regulation of an additional
arm of the adaptive immune response by CGRP. It will be of interest to determine whether CGRP
has divergent effects in regulating the differentiation of Th2 and Th9 cells.
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bEnd.3 endothelial cells (ECs) pre-exposed to calcitonin gene-related peptide (CGRP) bias
Langerhans cell (LC) antigen presentation to T cells toward an IL-17A response
RD Granstein, LL Stohl, M Manni, JA Wagner and W Ding Weill Cornell Medical College, New
York, NY
Recent work from our laboratory has suggested that ECs may play an important role in biasing LC
antigen presentation to T cells toward particular T helper cell subsets. We utilized cells of the trans-
formed BALB/c EC line bEnd.3 to examine this question and reported that exposure of bEnd.3 cells
to the bacterial product muramyl dipeptide (a ligand of the NOD2 receptor) induces them to bias
LC antigen presentation to responsive T cells toward the Th17 pole when co-cultured in antigen
presentation cultures with LCs and T cells. We have now used this system to examine the effects of
CGRP on EC biasing of the response to LC antigen presentation. bEnd.3 cells (2 x 105/well) were
plated in round-bottom 96-well plates in 200 μl of medium containing 100 nM CGRP. After 3-h,
plates were washed 4 times and 2 x 105 T cells from DO11.10 mice (BALB/c background) were
added to each well followed by addition of a fragment of chicken ovalbumin (cOVA323-339) to 10
μM. DO11.10 mice express transgenes in their T cell receptors such that they spontaneously rec-
ognize cOVA323-339. After 48-h of culture, supernatants were harvested and assayed for cytokine pro-
duction by ELISA. Addition of CGRP-exposed bEnd.3 cells significantly enhanced IL-6 and IL-17A
production compared to wells containing non-treated bEnd.3 cells while significantly inhibiting
interferon-γ, IL-4 and IL-22 responses. In a preliminary experiment, preteatment of LCs with siRNA
to IL-6 inhibited the effect on IL-17A (and IL-6) production. Control wells set-up identically but with-
out LCs yielded no significant response. These data show that CGRP induces the bEnd.3 cells to
bias LC antigen presentation towards an IL-17A response while inhibiting IL-4 and IL-22 responses.
The divergent regulation observed between IL-17A and IL-22 is of particular interest and may have
relevance to the putative role of CGRP in regulating inflammatory skin disorders. These findings
highlight the intricacies of regulation of cutaneous immunity by products of nerves.
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EpCAM (CD326) enables epidermal Langerhans cell motility and migration
MR Gaiser,1,2 T Lämmermann,3 X Feng,1 BZ Igyarto,4 DH Kaplan,4 L Tessarollo,5 RN Germain3 and
MC Udey1 1 Dermatology Branch, Center for Cancer Research, National Cancer Institute,
Bethesda, MD, 2 Department of Dermatology, University of Heidelberg, Heidelberg,
Germany, 3 Laboratory of Systems Biology, National Institute of Allergy and Infectious
Diseases, Bethesda, MD, 4 Department of Dermatology, Center for Immunology, University of
Minnesota, Minneapolis, MN and 5 Mouse Cancer Genetics Programm, Center for Cancer
Research, NCI-Frederick, Frederick, MD
After encountering epicutaneously-applied antigens, epidermal Langerhans cells (LC) migrate to
regional lymph nodes (LN) where they regulate the magnitude and quality of ensuing immune
responses. Detachment of LC from keratinocytes (KC) is likely to be central to regulation of LC migra-
tion. LC express high levels of EpCAM (epithelial cell adhesion molecule; CD326), a cell surface
protein characteristic of many carcinomas and implicated in intercellular adhesion and metastasis.
To gain insight into EpCAM function in vivo, we generated conditional knockout mice with EpCAM-
deficient LC. Epidermis from these mice contained increased numbers of LC with normal levels of
MHC, costimulatory molecules and T cell stimulatory activity in vitro. Migration of EpCAM-defi-
cient LC from skin explants was markedly inhibited while chemotaxis of dissociated LC was not.
Correspondingly, ability of contact allergen-activated, EpCAM-deficient LC to exit epidermis in
vivo was delayed and strikingly fewer hapten-bearing LC subsequently accumulated in LN. Atten-
uated migration of EpCAM-deficient LC resulted in enhanced contact hypersensitivity responses as
previously described in LC-deficient mice. Intravital microscopy revealed reduced translocation and
dendrite motility in EpCAM-deficient LC in vivo in contact allergen-treated mice. These results con-
clusively link EpCAM expression to LC motility/migration and immune regulation. EpCAM may
promote LC migration from epidermis by decreasing LC-KC adhesion and modulate intercellular
adhesion and cell movement within epithelia during development and carcinogenesis in an anal-
ogous fashion.
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Physiologic induction of monocyte-to-dendritic cell maturation: Delivery of required second
signal via internalization of biodegradable PLGA nanoparticles
S Saluja,1 D Hanlon,1 D Khalil,1 F Sharp,2 T Fadel,2 E Robinson,1 T Fahmy,2 R Tigelaar1 and
R Edelson1 1 Dermatology, Yale Univ, New Haven, CT and 2 Biomedical Engineering, Yale
Univ, New Haven, CT
We have recently shown in vitro that transient platelet-monocyte interaction under flow condi-
tions, providing shear stress, initiates differentiation of monocytes to dendritic cells (DCs), in the
absence of additional stimuli, such as exogenous growth factors. In vivo, activated platelets express
adhesion molecules such as P-selectin, thereby providing reactive surfaces for trafficking mono-
cytes. Because monocytes are phagocytic cells, we hypothesized that polymeric nanoparticles (NPs),
which are FDA-approved and biodegradable/biocompatible, may act as a “danger signal” leading
to enhanced monocyte- to-DC maturation. To test this hypothesis, a parallel-plate flow chamber was
used to pass mononuclear cells over plastic-surface-immobilized platelets. Treated cells were incu-
bated overnight to initiate the differentiation process, after which they were cultured for another
24h either in the absence or presence of 100μg/ml poly(lactic-co-glycolic)acid (PLGA) NPs. Using
flow cytometry and confocal microscopy, we determined that: (1) > 95% of human CD11c+ cells
internalized NPs, which localized in the cytoplasm of the cells; (2) incorporation of NPs led to 6-
fold (p=0.001) and 8-fold (p=0.02) up-regulation of HLA-DR+/CD83+ and CD80+/CD86+ pheno-
type (typical of maturing DCs), respectively, and 2-fold (p=0.0003) down-regulation of CD14 marker
(typical of monocytes); (3) >90% of cells were viable after overnight incubation with NPs. These
findings reveal that platelets-monocyte interaction followed by addition of PLGA NPs can directly
contribute to rapid (2 day) monocyte-to-DC maturation, in the absence of addition of cytokines.
Because of its physiologic basis and avoidance of both special tissue culture facilities and addition
of supra-pharmacologic levels of cytokines, this rapid and efficient system may enable the in vitro
production of large numbers of DC for both experimental and clinical use.
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Identification of genes to reliably differentiate mycosis fungoides from psoriasis
DV Chan,1,3 TS Hake,1,3 F Kartono,1,3 P Porcu2,3 and HK Wong1,3 1 Div. of Dermatology, Ohio
State Univ., Columbus, OH, 2 Div. of Hematology, Ohio State Univ., Columbus, OH and 3
The James Comprehensive Cancer Center, Ohio State Univ., Columbus, OH
Accurate diagnosis and differentiation of psoriasis (PSO) from mycosis fungoides (MF) type cuta-
neous T cell lymphoma (CTCL) can sometimes be challenging, even with a good clinical exam and
review of pathology. Early, accurate detection can lead to a better treatment course and potentially,
an improvement in survival, especially in MF. In this study, the objective was to determine if spe-
cific genes can be used to reliably differentiate MF from PSO in full thickness skin biopsies. Array
data for PSO, non-lesional PSO, CTCL, and normal lesions were downloaded from the NCBI and
analyzed using Agilent GeneSpring. Genes that were differentially expressed in PSO vs. CTCL tumors
were selected for further consideration. In parallel, the same PSO data sets were compared to gene
sets from a different platform that corresponded to early stage IA to IB MF. Data were normalized,
and genes with at least a 2.5-fold differential expression in PSO vs. CTCL were further considered.
After deriving a consensus list of genes with at least a 2.5-fold differential expression in both types
of MF lesions vs. PSO, we selected 24 of these genes predicted to have highly differential expres-
sion and validated their expression in skin biopsies from 13 patients with MF (Stage IA/IB (3), IIB
(6), IIIA/IIIB (2), and IVA (2)), 6 patients with PSO, and 3 normal controls. Data were normalized
within each sample using β2 microglobulin, and the relative normalized expression of each gene
was compared in each MF sample vs. PSO. Relative fold expression of each gene was assessed in
each MF stage vs. PSO as well as in aggregate vs. PSO. Four of the 24 genes showed consistent dif-
ferential expression, and their fold expressions in the aggregate MF cohort vs. PSO were found to
approach significance with p values approaching 0.05. These data suggest that antimicrobial pep-
tides, protease inhibitors, and inflammatory cytokines may be useful in differentiating MF from
PSO in diagnostically challenging cases.
582
IL-17C and TNFα synergize to produce a psoriasis-like gene signature in human keratinocytes
and an inflammatory skin phenotype in K5-IL-17C transgenic mice
A Johnston,2 SM Dawes,1 D Diaconu,1 W Fu,1 M Riblett,2 JT Elder,2 JE Gudjonsson,2
TS McCormick1 and NL Ward1 1 Dermatology, Case Western Reserve University, Cleveland,
OH and 2 Dermatology, University of Michigan, Ann Arbor, MI
IL-17C is a functionally distinct member of the proinflammatory IL-17 cytokine family. Previous
work demonstrated that IL-17A, produced by Th17 cells, mast cells, γδT cells and neutrophils binds
IL-17RA/C and synergizes with TNFα to induce >300 disease-signature genes in the psoriasis tran-
scriptome. We now demonstrate that IL-17C, not IL-17A, is the most abundant IL-17 family mem-
ber in psoriasis skin (1058pg/ml vs 8pg/ml protein; P<0.001) and is expressed by keratinocytes (KCs),
endothelial cells (ECs) and leukocytes. Interestingly, primary human KCs fail to respond to IL-17C
(200ng/ml) stimulation alone, but synergistic stimulation with IL-17C and TNFα (2ng/ml) produced
the same inflammatory gene response as that elicited by IL-17A/TNFα. In contrast, preliminary data
demonstrate that human dermal ECs stimulated with IL-17C produce 10-fold more TNFα than unstim-
ulated cells; thus KC-derived IL-17C coupled with EC-derived TNFα may initiate a pro-inflamma-
tory KC-EC feedback loop. To address IL-17C/TNFα synergy in vivo, we genetically engineered mice
to overexpress IL-17C in KCs. K5-IL-17C mice spontaneously develop modest acanthosis preceded
by increases in ECs and TNFα gene expression. Importantly, skin injury (e.g. tape stripping) resulted
in severe epidermal hyperplasia and robust cutaneous lymphocyte infiltration along with increased
TNFα (10-fold), IL-17A (32-fold), IFNγ (8-fold), IL-1α/β(~10-fold), IL-12/23 (~15-fold) S100A8/A9
(~100-fold), and DefB3 (163-fold)(all P<0.05). These changes improved following 8 weeks of sys-
temic inhibition of TNFα. Together these in vitro and in vivo results identify a key role for IL-17C/TNFα
synergy in the development of psoriasisform skin inflammation. Since numerous KCs activated in
psoriasis tissue produce excess IL-17C compared to relatively modest numbers of IL-17A produc-
ing cells, IL-17C may provide a broader target for developing therapeutic strategies.
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Circulating central memory T cells are increased and have different cytokine production prop-
erties in patients with psoriasis
M Hayashi, T Furuhashi, E Nishida, C Saito, K Torii and A Morita Nagoya City University
Graduate School of Medical Sciences, Nagoya, Japan
Central memory T cells (TCM) are similar to naive T cells and express the lymph node homing recep-
tors L-selectin (CD62L) and CCR7. TCM have fewer effector functions, but proliferate vigorously
and develop into effector T cells through antigen stimulation. Psoriasis patients have elevated lev-
els of CD4+CCR7+ cells, but the pathogenesis of TCM in psoriasis is unclear. We therefore inves-
tigated the levels of CCR7+ T cells and CCR7+CXCR5+ T cells in the peripheral blood of psoriasis
patients and the relationship between TCM and Th17/Th22 cells. CD4+ cells were isolated from
peripheral blood monocytes and CCR7+ T cells and CCR7+CXCR5+ T cells were subjected to flu-
orescence-activated cell sorting analysis for TCM. The levels of CCR7+ T cells and CCR7+CXCR5+
T cells were significantly higher in psoriasis patients (25.97 ± 12.94%, 9.98 ± 7.25% n=120) than
in healthy controls (14.32 ± 8.54%, 1.99 ± 0.958% n=5). Furthermore, the level of CCR7+ and
CCR7+CXCR5+ T cells was significantly increased in patients with severe psoriasis. In addition, the
levels of CCR7+ T cells in psoriasis patients with a Psoriasis Area and Severity Index (PASI) score
greater than 30 significantly correlated with the PASI score (r=0.424 p=0.049). The level of CCR7+
T cells in patients with a PASI score greater than 20 significantly correlated with the level of Th22
cells (r=0.310 p=0.032). In vitro, CD4+CCR7+Tcells and CD4+CD62L+Tcell were isolated and cul-
tured in the presence of interleukin (IL)-1b, IL-6, IL-21, or tissue growth factor-b. Expression of IL-
17A and IL-22 was estimated by reverse transcription-polymerase chain reaction. TCM from psori-
asis patients showed a significantly greater ability to produce IL-17A and IL-22 compared with
TCM from controls. These findings suggest that TCM are strongly associated with the pathogenesis
and degree of severity of psoriasis, and might be a precursor of pathogenic T cells in psoriasis.
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CCR6 is required for epidermal trafficking of (and IL22 production by) γδ-low T cells in an
IL23-induced model of psoriasiform dermatitis
T Mabuchi,1 T Singh,2 T Takekoshi,1 J Farber2 and S Hwang1 1 Dermatology, Med Coll of WI,
Milwaukee, WI and 2 Inflammation Biol. Sect., NIAID, Bethesda, MD
Cytokine components of Th17 pathway, including IL23, IL17, IL22, and CCR6 and its ligand CCL20
play vital roles in human psoriasis by promoting inflammation and epidermal proliferation. Recently,
we have demonstrated that CCR6+, γδ-low expressing T cells (termed GDL T cells) that produce
high levels of IL17 and IL22 may also play important roles in an IL23-mediated, CCR6-dependent
murine model of psoriasiform dermatitis, and others have demonstrated that an IL22-producing pop-
ulation of γδ T cells is increased in the skin of patients with psoriasis. In this study, we use antibod-
ies against CCL20 as well as CCR6-deficient (KO) and WT mice to analyze the trafficking patterns
of GDL T cells and to determine the role of CCR6 in the development of IL23-mediated dermatitis.
Herein, CCL20 was found to be highly upregulated in IL23-injected WT mouse ear skin as early as
24 hours after initial treatment. Confocal microscopy showed large numbers of CCR6+ cells in the
epidermis of IL23-, but not PBS-, injected WT mice. Co-injection of IL23 with neutralizing anti-
CCL20 mAbs was found to inhibit the psoriasiform dermatitis as well as the recruitment of GDL T
cells to the epidermis. Following skin injection of IL23 in CCR6 KO mice, GDL T cells largely failed
to accumulate in the epidermis. While total numbers of GDL T cells in the dermis of WT and CCR6
KO mice were equivalent following IL23 injection, there was a ~70% reduction in the proportion
of IL22+ GDL T cells in the dermis of CCR6 KO mice (vs. WT mice), suggesting that effector func-
tion as well as epidermal recruitment of GDL T cells may be severely impacted in CCR6-deficient
mice. Our data confirm that CCR6 and CCL20 may be highly relevant targets for therapy in IL23-
mediated skin diseases, including psoriasis, and reveal that CCR6 may have roles other than traf-
ficking in IL23-mediated skin disease.
581
Botulinum neurotoxin A decreases infiltrating cutaneous lymphocytes and improves acan-
thosis in psoriasiform KC-Tie2 mice
NL Ward,1 KD Kavlick,1 D Diaconu,1 KA Michaels,1 SM Dawes1 and E Gilbert2 1 Dermatology,
Case Western Reserve University, Cleveland, OH and 2 Dermatology, SUNY Downstate,
Brooklyn, NY
The nervous system plays a role in psoriasis pathogenesis evidenced by increases in nerve fiber
density, calcitonin gene related peptide (CGRP) and substance P (SP) in psoriatic skin and the clin-
ical observation that psoriasis remission occurs following loss of innervation. However, the neural
mechanisms sustaining disease pathogenesis remain unclear. We recently demonstrated surgical
denervation of KC-Tie2 mouse dorsal skin significantly improved psoriasiform disease severity,
including decreased acanthosis and reduced infiltrating CD11c+ dendritic cell (DC) and CD4+ T cell
numbers. Reconstitution of SP or CGRP in denervated KC-Tie2 skin prevented improvement in the
phenotype and inhibition of SP or CGRP in innervated KC-Tie2 skin recapitulated the denervation
effects in a neuropeptide specific manner (JID,131(7):1530). The current study investigated whether
one intradermal injection of botulinum toxin A (BoNT-A), a known inhibitor of CGRP and SP nerve
derived release, would provide similar levels of improvement in skin disease. Adult KC-Tie2 mice
(5 months old) had their dorsal skin injected once with intradermal BoNT-A (Dysport®; 9units/kg)
or saline in anatomically separate locations. BoNT-A injected skin showed significant decreases in
acanthosis compared to saline injected skin 2 weeks (17%; P=0.03; n=5) and 6 weeks (25%; P=0.01;
n=6) following the initial injection. Dermal CD11c+ DC infiltration was significantly reduced in
BoNT-A injected skin compared to saline injected skin at 2 weeks (29%; P=0.002) and 6 weeks
(38%; P<0.0001) and CD4+ cell numbers also decreased significantly in BoNT-A injected skin
compared to saline injected skin at 2 weeks (24%; P=0.02) and 6 weeks (34%; P<0.002). These
results demonstrate significant improvement in psoriasiform skin inflammation and epidermal hyper-
plasia following one injection of BoNT-A and support the use of BoNT-A as a supplemental ther-
apy for recalcitrant plaque psoriasis following topical or biologic regimens.
585
Dendritic cell trafficking in skin is regulated by hair follicles via chemokine production
K Nagao,1 T Kobayashi,1 K Moro,2 K Kabashima,3 M Ohyama,1 Y Cho,5 BE Clausen,4 MC Udey5
and M Amagai1 1 Dermatology, Keio University School of Medicine, Tokyo, Japan, 2
Immunology & Microbiology, Keio University School of Medicine, Tokyo, Japan, 3 Kyoto
University, Kyoto, Japan, 4 Erasmus University Medical Center, Rotterdam, Netherlands and 5
CCR, NCI, NIH, Bethesda, MD
Hair comprises a vital barrier for mammals. Langerhans cells (LC) are unique resident epidermal
dendritic cells that associate with hair follicles (HF) for unknown reasons. LC self-renew in unper-
turbed skin and arise from monocyte-derived precursors during inflammation, but LC origins are
incompletely characterized. Details of routes and mechanisms by which LC repopulate epidermis
also remain to be elucidated. Herein, we show that fate mapping or selective depletion of mono-
myeloid precursors utilizing Lysozyme M-Cre mice (crossed to CAT-CAG-eGFP or ROSA26-diph-
theria toxin mice) reveals lysozyme M-expressing LC precursors (pre-LC). Pre-LC rapidly infiltrated
perturbed epidermis via HF in a CCR2/CCR6-dependent manner, as shown in bone marrow trans-
plantation experiments. CCR8-deficiency, in contrast, enhanced LC repopulation. We sorted HF ker-
atinocytes into 4 subsets and found that HF differentially expressed mRNAs encoding chemokines
that represent CCR2/6 ligands. The infundibulum expressed CCL2 and the isthmus expressed CCL20.
Chemokine expression was not detected in CD34+ HF bulge cells in the basal layer, but a distinct
group of suprabasilar bulge cells that selectively expressed sphingosine-1-phosphate receptor 1
exclusively produced the CCR8 ligand CCL8, which was confirmed at the protein level. Thus, dis-
tinct HF subsets differentially facilitated or inhibited recruitment of LC via chemokine production.
In skin grafts that were simultaneously transplanted onto nude mice, recipient-derived pre-LC repop-
ulated hair-bearing, but not hairless skin, establishing HF as epidermal portals of entry for LC. Col-
lectively, HF recruit and facilitate entry of dendritic cells to sites of epidermal perturbation, sug-
gesting a new paradigm regarding immune cell trafficking during skin inflammation.
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Therapeutic effect of protein transduction domain-conjugated methotrexate in imiquimod-
induced psoriasiform dermatitis model
D Byamba,1,2 D Kim,1 W Wu,1 T Kim,1 H Jee,1 S Lee3 and M Lee1 1 Department of Dermatology
and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul,
Republic of Korea, 2 Brain Korea 21 Project for Medical Science, Yonsei University College of
Medicine, Seoul, Republic of Korea and 3 Department of Biotechnology, College of Life
Science and Biotechnology, Yonsei University, Seoul, Republic of Korea
Systemic methotrexate (MTX) is an effective treatment for psoriasis being initially used more than
50 years ago. However, drug-related toxicities such as myelosuppresion and hepatotoxicity deter
physicians from a prolonged prescription of MTX. These adverse effects may be minimized by admin-
istering MTX by topically using an effective drug delivery system. The aim of this work is to evalu-
ate the efficacy and safety of cell permeable protein transduction domain (PTD)- conjugated MTX
in mouse model of psoriasis. Topical imiquimod (IQM) induced psoriasiform dermatitis model was
used as an in vivo psoriasis model. In brief, IQM cream was applied daily on the shaved back of
BALB/C female mice for 7 days. Since day 4, treatments were given as an intraperitoneal (IP) MTX
injection (35/mg/kg) or topical application of PTD-MTX in two different concentrations (0.1% and
1% w/w). On day 8, clinical severities and histological changes were evaluated, and immunologi-
cal changes in spleen and lesional skin were analyzed using flow cytometry. Modified PASI score
of 1% PTD-MTX applied mice was lowest (3.13±0.38) followed by 0.1% PTD-MTX applied
(4.25±0.38), IP MTX injected (6.00±0.52), and IQM alone applied group (7.63±0.63) in ascending
order. Spleen size and compositions of immune cells were not altered by topical PTD-MTX appli-
cation in IQM-applied mice. However, flow cytometric analysis of epidermal and dermal cell sus-
pensions revealed significant normalization of alterations in pathogenic immune cells infiltrations.
Hepatotoxicity and nephrotoxicity were observed in IP MTX group but not in PTD-MTX-applied
mice. In conclusion, topically applied, PTD-conjugated MTX ameliorated IQM-induced psoriasi-
form skin inflammation without systemic immune suppressive or toxic effect.
587
Phenotypic analysis of dendritic cell polarization in the skin-draining lymph nodes of cuta-
neous T-cell lymphoma
T Hamada,1 K Tada,1,2 K Asagoe,3 H Umemura,1 M Otsuka,1 O Yamasaki,1 Y Aoyama,1 K Fujii1 and
K Iwatsuki1 1 Dermatology, Okayama University Graduate School of Medicine, Dentistry, and
Pharmaceutical Sciences, Okayama, Japan, 2 Dermatology, Okayama City Hospital,
Okayama, Japan and 3 Dermatology, Okayama Medical Center, Okayama, Japan
Mycosis fungoides (MF) starts and progresses predominantly in skin lesion, eventually to lymph
node (LN) according to the disease progression. Although the role of dendritic cells (DCs) in cuta-
neous T-cell lymphoma (CTCL) has been gradually elucidated, little has been known about DC
subsets and their properties in the node involvement. To clarify the immnunological milieu of the
skin-draining LN, we first examined DC phenotypes and their distribution in the resected LNs from
patients with CTCL (n=12), and sentinel nodes (control group; negative for metastatic melanoma;
n=8). Immunohistochemical staining was performed using an antibody panel, including S-100,
CD1a, DC-LAMP, DC-SIGN, Langerin and CD123. In the TNM classification for CTCL, eight of the
12 LNs were of N1, and four were of N2. The density of DC-LAMP+ cells and the proportion of DC-
LAMP+ cells to all DCs (S-100+ cells) were significantly increased in the CTCL group in the para-
cortex as compared with those in the control group (the median of the density: 475/mm 2 and
225/mm2, respectively, p=0.0036; the median of the proportion: 80.5% and 42.5%, respectively,
p=0.0018). In contrast, the proportion of DC-SIGN+ cells was significantly decreased in the CTCL
group in the paracortex as compared with those in the control group (12% and 36.5%, respec-
tively, p=0.029). No significant difference was observed in the density or the proportion of CD1a+
and Langerin+ cell between the two groups. Our results suggest that the increase of mature DC-
LAMP+ DCs with concomitant decrease of immature DC-SIGN+ DCs in the skin- draining nodes
in CTCL might reflect a certain immune deviation corresponding to the disease progression of CTCL.
588
Induction of IL-21-producing CD4+ T cells by human resident cutaneous dendritic cells
H Fujita,1 JA Carucci2 and JG Krueger1 1 Laboratory for Investigative Dermatology, The
Rockefeller University, New York, NY and 2 Department of Dermatology, New York University
Langone Medical Center, New York, NY
IL-21 is a T-cell derived cytokine which has pleiotropic actions including co-stimulation of B cell
differentiation into plasma cells and immunoglobulin production, co-mitogen of T cells, stimula-
tion of natural killer and CD8+ T cell cytotoxic function, and induction of keratinocyte prolifera-
tion. Among CD4+ T cells, Th17 and T follicular helper cells are thought to be the most prominent
producers of this cytokine. In humans, development of IL-21-producing cells from naïve CD4+ T
cells has shown to be largely mediated by dendritic cell (DC)-derived IL-12. Clinically, IL-21 plays
an pivotal role in anti-tumor immunity. Furthermore, IL-21 is shown to be highly expressed in the
lesional skin of inflammatory skin diseases, such as atopic dermatitis and psoriasis, indicating the
importance of this cytokine in skin immunity. In this study, using allogeneic mixed luekocyte reac-
tion system, we examined whether resident cutaneous DCs can induce T cells producing IL-21
from naïve CD4+ T cells. For this purpose, we employed Langerhans cells (LCs) and resident der-
mal DCs directly isolated from human skin. We found that dermal DCs are more efficient than LCs
in activating CD4+ T cells to produce IL-21. Induced IL-21 production was almost completely
independent of IL-17 production in both LC-stimulated and demal DC-stimulated T cells. Finally,
although induction of IL-21-producing T cells by monocyte-derived DCs and dermal DCs were con-
siderably inhibited by neutralizing anti IL-12/IL-23p40 Ab by 64.5% and 49.9%, respectively, IL-
12/IL-23p40 neutralization did not affect the induction of IL-21-producing T cells by LCs. These
results are consistent with the reported inability of human LCs to secrete bioactive IL-12 and indi-
cate a yet unknown alternative mechanism to IL-12/IL-23 to develop IL-21+CD4+ T cells. Our results
also have an implication for the use of cutaneous DCs for immunotherapy.
589
Th9 lymphocytes contribute to human allergic contact dermatitis
J Liu,1 A Tammaro,2,1 N Girardi,3,1 A Nakazono,4,1 R Fishelevich1 and AA Gaspari1 1 Dermatology,
University of Maryland Baltimore, Baltimore, MD, 2 Dermatology, University of Rome, Rome,
Italy, 3 Allegheny MCP University of the Health Sciences, Philadelphia, PA and 4
Dermatology, Kyushu University, Fukuoka, Japan
Th9 lymphocytes and its associated cytokine, IL-9 have been implicated in allergic asthma. We stud-
ied whether Th9 play a role in human allergic contact dermatitis (ACD). Skin biopsy specimens were
obtained from seven clinically relevant, positive patch tests from non-atopic patients, and cytokine
gene expression was assayed using qRT-PCR. The mean relative gene expression of IL-9, and the
Th9-associated transcription factor, PU.1 were elevated on average 2-and 3 -fold higher than paired
control skin. This was equivalent gene expression for IFN-g, IL-4 and IL-17A, which are genes com-
monly associated with ACD. Using regression analysis, we correlated gene expression of IL-9 in
ACD with other genes, and found a significant correlation with CD3e (R=0.810, p<0.02), IL-4
(R=0.88, p<0.007), PU.1(R=0.81, p<0.009) and eotaxin (R=0.95, p<0.04), but no correlation with
IFN-g or IL-17A. Utilizing two color immunochemistry on skin biopsy specimens of ACD, we iden-
tified PU.1+/CD3+, or PU.1+/CD4+ cells (i.e., Th9 lymphocytes) (but not in the CD8+ subset) in
the inflammatory infiltrate both in the epidermis and dermis (positive patch tests to nickel, epoxy,
thimerosal, diazolidonyl urea, tixocortolol pivalate), at an average frequency of 4%. Lymphocyte
responses from three different patients with nickel allergy were studied for allergen-specific pro-
duction of IL-9, IFN-g, IL-2, IL-4 in response to in vitro challenge with nickel or an antgen (cobalt).
We observed an allergen-specific dose-response production of IL-9 (peak production of 60 pg/ml)
in conjunction with IFN-g (35 pg/ml peak), IL-4 (4 pg/ml peak) and IL-2 (15 pg/ml peak). However,
there was no IL-9 or other cytokines produced in response to an irrelevant metal salt such as cobalt.
Thus, these data suggest that Th9 lymphocytes contribute to the pathophysiology of ACD, and demon-
strate a novel role for this cell type in human allergic skin disease.
590
Selective interaction between DC and Treg relies on the chemotactic activity of adenosine
S Ring, A Enk and K Mahnke Dermatology, Ruprecht-Karls-University, Heidelberg, Germany
Suppression of the sensitization phase of contact hypersensitivity (CHS) reactions by
CD4+CD25+Foxp3+ regulatory T-cells (Treg) is mediated by interaction between dendritic cells (DC)
and Treg in draining lymph nodes. To analyze why DC preferably interact with Treg, we prepared
in vitro cocultures of isolated murine Treg with syngeneic DC. We observed rapid formation of aggre-
gates between the cells within 2h. Even in presence of CD4+ T-cells the formation of aggregates
occurred selectively between Treg and DC. Analysis of the migratory behavior of individual DC in
cocultures with Treg or CD4+ T-cell, respectively, showed increased motility of the DC in presence
of Treg as opposed to cocultures with CD4+ T-cells. Further analysis of the chemotactic activity of
Treg using Boyden-chambers revealed a significantly higher migration rate of DC towards the Treg
as compared to the migration towards conventional CD4+ T-cells or medium. Blocking the adeno-
sine production of Treg via inhibition of the ectonucleotidase CD39 caused a complete inhibition
of the DC-Treg aggregate formation and the chemotactic activity of Treg on DC, which could be
overcome by application of exogenous adenosine to the cocultures. Thus our data indicate that
adenosine produced by Treg act as chemoattractant for DC and modulates the formation of Treg/DC
aggregates, resulting in an immunosuppressive DC-phenotype.
591
Alcohol consumption inhibits Th1-skewed CHS responses independent of hapten strength
R Brand,1,2 J Stottlemyer1 and LD Falo, Jr.1 1 Dermatology, University of Pittsburgh, Pittsburgh,
PA and 2 Medicine, University of Pittsburgh, Pittsburgh, PA
Alcohol abuse interferes with both innate and adaptive immune systems leading to poor clinical
outcomes after infection or injury. Greater knowledge of the mechanisms by which alcohol alters
immune function is necessary to develop strategies capable of reversing these changes. Contact
hypersensitivity reactions (CHS) are dendritic cell dependent, antigen specific, T cell-mediated
immune responses triggered by skin exposure to haptens. We have previously reported that ETOH
consumption inhibits CHS responses to the Th1 skewing sensitizer DNCB. In contrast, alcohol con-
sumption did not diminish the CHS response triggered by the Th2 skewing sensitizer FITC. These
studies were extended to determine if ETOH inhibition of Th1-induced CHS is dependent on rela-
tive hapten strength. CHS studies were performed on alcohol-fed mice and their pair fed controls
with oxazolone, a strong Th1 skewing hapten, DNCB, a moderate Th1 inducer and cinnamalde-
hyde, a weak Th1 hapten. ETOH consumption inhibited CHS swelling for all three Th1 skewing hap-
tens. The data suggest that the immunosuppressive effects of alcohol ingestion are not overcome by
modulation of hapten strength alone. They suggest that alternative approaches, including the use of
potent adjuvants may be necessary to overcome alcohol induced immunosuppression.
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Broad spectrum anti-inflammation activity of a novel benzoxaborole compound, AN4161
C Dong, H Sexton, C Chen, X Fan, C Virtucio, J Plattner, W Bu, A Wu, L Liu, K Jarnagin and
Y Freund Anacor Pharmaceuticals, Palo Alto, CA
AN4161, 3-chloro-2-fluoro-N-(1-hydroxyl-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)-6-(trifluo-
romethyl)benzamide, developed from a boron-based drug discovery platform, inhibited TCR-medi-
ated IL-2, TNFα, IFNγ, IL-4 and IL-13 secretion from human T cells with IC50s < 0.3 μM. This com-
pound also blocked LPS-induced TNFα, IL-1β and IL-6 synthesis from human monocytes with IC50s
ranging from 0.2 to 0.7 μM. AN4161 prevented the activation of T cells, as evidenced by a decrease
in surface expression of CD25 and CD69, and selectively promoted apoptosis/death of anti-
CD3/CD28-stimulated T cells, whereas it showed < 30% inhibition of resting T cell and monocyte
viability. Oral administration of AN4161 to CD-1 mice, 30 mg/kg, once every other day for 14
days, did not show effects on lymphocytes, neutrophils or other hematological parameters in plasma.
No changes were noted in the population of T cells (CD3+), T cell subsets (CD4+ or CD8+), B cells
(B220+) or macrophages/monocytes (CD11b+) in splenocytes. The in vivo observations echoed the
in vitro selective apoptotic effect of AN4161 on activated T cells, suggesting therapeutic potential
of this molecule for T lymphoma and aberrant T cell activation-related inflammation. AN4161 had
an outstanding mouse PK profile with low plasma clearance of 41 mL/hr/kg (IV) and a long half-life
of 13.3 hr (PO). Oral administration of AN4161, 30 mg/kg, once every other day, strongly suppressed
collagen-induced arthritis in mice over 20 days. Topical administration of AN4161 reduced PMA-
induced ear swelling and oxazolone-induced delayed-type hypersensitivity. The efficacy of AN4161
in in vivo disease models supports its potential therapeutic application for inflammatory diseases.
594
Flt3L expands skin and skin draining LN resident DC and improves subcutaneous protein
immunization to HIV gag with microbial mimics
N Anandasabapathy, R Feder, MP Longhi, S Mehandru, C Cheong, D Ruane, L Brane, A Teixeira
and RM Steinman Laboratory of Cellular Physiology and Immunology (Steinman Lab),
Rockefeller University, New York, NY
Immune modulatory agents are needed to potentiate subcutaneous vaccination and improve T cell
immunity. In this study, we evaluated the dendritic cell (DC) hematopoietin Fms-like tyrosine
kinase 3 ligand (Flt3L) and subcutaneous HIV gag protein immunization. Flt3L was detected in serum
early after protein vaccine immunization to HIV gag with adjuvant. Administration of Flt3L expanded
several migratory DC (mDC) populations that capture and traffic antigens to the skin draining lymph
node (LN), in addition to LN resident conventional (cDC) and plasmacytoid (PDC) DC. Flt3L treat-
ment improved the T cell response to s.c. protein vaccination by 4.5 fold, and deletion of Flt3 reduced
immunization by 50%. Flt3L enhanced CD4+ and CD8+ IFN-gamma effector responses, prolifer-
ation, and humoral immunity to HIV gag and adjuvant, with markedly improved mucosal immu-
nity in the lungs and lamina propria. Flt3L enhanced the capture of DC-targeted antibodies by both
migratory and classical LN resident DC. These results indicate that Flt3L expands a rich subcuta-
neous network of DC towards improved protein immunization, supporting its use as a clinical
agent to improve cutaneous and subcutaneous immunity.
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Clarification of the roles of cutaneous dendritic cell subsets in the elicit ation phase of con-
tact hypersensitivity response
Y Natsuaki,1,2 G Egawa,1 S Nakamizo,1 H Tanizaki,1 T Hashimoto,2 Y Miyachi1 and K Kabashima1
1 Dermatology, Kyoto University Graduate School of Medicine, Japan, Kyoto, Japan and 2
Dermatology, Kurume University School of Medicine, Japan, Kurume, Japan
In contact hypersensitivity (CHS), it has been thought that the antigen presentation takes place in
the draining lymph nodes during the sensitization phase, whereas predominantly in the skin dur-
ing the elicitation phase. The role of skin dendritic cells (DCs) has been extensively studied, how-
ever, the role of the DC subsets during the elicitation phase remains largely unknown. In this study,
we analyzed the dynamics of skin-resident DCs in the elicitation phase of CHS using a two-photon
microscopy system. We examined the morphological changes and kinetics of Langerhans cells (LCs)
and dermal DCs (dDCs) before and after hapten application. We revealed that LCs were almost static
throughout the elicitation phase while they actively extended their dendrites. In contrast, dDCs
actively migrated and transiently halted their migration immediately after hapten application. There-
after dDCs accumulated locally and interact with sensitized T cells around hair follicles to form clus-
ters. To further investigate the role of cutaneous DCs, we evaluated the antigen presenting capac-
ity of skin DC subsets by subset-specific depletion using CD11c-DTR (diphtheria toxin receptor)
and Langerin-DTR mice in combination with bone marrow chimeric techniques. Depletion of LCs
alone in the elicitation phase induced a prolonged CHS response as compared with the control
mice. On the other hand, depletion of both LCs and dDCs impaired CHS. These results suggest that
dDCs were essential for elicitation of CHS and that LCs may have an opposite role. Therefore, our
study provides a fundamental knowledge for understanding the mechanism and roles of skin den-
dritic cells in the elicitation phase of CHS.
595
Conversion of monocytes to dendritic cells by platelet signaling
D Khalil, E Robinson, S Saluja, J Futterleib, D Hanlon, R Tigelaar and R Edelson Dermatology,
Yale University, New Haven, CT
Our group has previously reported that human monocytes can be efficiently and rapidly converted
to dendritic antigen presenting cells by transient adherence to platelets immobilized on a plastic
surface, without the addition of exogenous growth factors. Conversion requires platelet surface P-
selectin and shear forces generated by media flow. To enhance the DC yield, we created an ex vivo
circuit maximizing the impact of two responsible variables: flow rates and DC procurement from
the immobilized platelet layer. Briefly, a polystyrene surface was first coated with human fibrino-
gen and secondarily with high-density platelets. The platelets then engaged monocytes under phys-
iological shear stress, followed by fibrinolysis via plasminogen activators, thereby allowing for the
release and collection of the induced DC. The newly maturing DC were then cultured for 22 hours
and phenotyped using multi-parametric flow cytometry. Prior to their enhanced release, 41.8%±17.2
(n=14) monocytes entering the DC pathway persistently adhered to the immobilized platelet layer.
Streptokinase mediated fibrinolysis permitted isolation of 46.8%±10.2 (n=3) of these adherent incip-
ient DC, confirmed qualitatively by live video microscopy and quantitatively by flow cytometry.
Compared to less avidly adherent incipient DC, these secondarily released DC had higher densi-
ties of membrane HLA-DR/CD83 (12.6±3.1 vs 4.8±3.0; p=0.04), markers of DC differentiation.
Together, these data reveal that the most adherent incipient DC are relatively the most mature and
that their procurement can be enhanced by exposure to streptokinase. This physiologic method of
DC production efficiently yields large populations of DC, potentially valuable for in vitro and in vivo
study and clinical application.
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Galectin-1 can bind human melanoma-specific CD8+ T cells and trigger immunosuppression
JE Geddes,1,3 F Cedeno-Laurent,1,3 MO Butler2,3 and CJ Dimitroff1,3 1 Dermatology, Brigham &
Women’s Hospital, Boston, MA, 2 Department of Medicine, Dana-Farber Cancer Institute,
Boston, MA and 3 Harvard Medical School, Boston, MA
Galectin-1 (Gal-1) is a secreted carbohydrate-binding protein that binds N-acetyllactosamines on
N- and O-linked glycans expressed on membrane proteins (ligands) of certain T cell subsets. Depend-
ing on local concentrations in tissues, Gal-1 can either trigger apoptosis or the synthesis of regula-
tory cytokines. Several studies, in fact, demonstrate that Gal-1 can regulate Th1 and Th17 cell
responses by inducing an immunoregulatory signature that ultimately results in cell death or Th2
cytokine production, namely IL-10. However, relatively few studies have focused on the role of Gal-
1 binding to its ligands on CD8+ T cells, particularly in the context of tumor immune evasion. Sev-
eral groups, including our own, have recently demonstrated that melanoma cells secrete an abun-
dance of Gal-1, which in turn can direct the level and cytolytic function of CD8+ T cells in
melanoma-bearing hosts. Coupling this observation with Gal-1’s well-known immunoregulatory
effects on Th cells has led to the hypothesis that Gal-1 elicits tumor immune escape by suppressing
the quantity and function of melanoma Ag-specific CD8+ T cells. To test this hypothesis, we employed
a new and innovative method to generate melanoma-specific CD8+ T cells and first assayed Gal-1
binding to in vitro-expanded human melanoma antigen recognized by T cells (MART-1)-specific
CD8+ T cells and found that, compared with weak binding to naïve CD8+ T cells, Gal-1 avidly
bound MART-1-specific CD8+ T cells. In addition, we found that Gal-1 either induced CD8+ T cell
death or altered the CD8+ T cell cytokine profile by reducing the percentage of perforin+ MART-1-
specific CD8+ T cells. These findings indicate that Gal-1 can play an immunoregulatory role on anti-
tumor CD8+ T cells and may contribute to attenuated melanoma immunity and, perhaps, even rea-
son for the modest success of adoptive CD8+ T cell therapy for the treatment of melanoma.
597
Macrophages bias Langerhans cell antigen presentation to CD4+ T cells toward an IL-17A
response
J Lee, M Manni, W Ding and RD Granstein Weill Cornell Medical College, New York, NY
Several lines of evidence suggest that macrophages (MΦs) play a role in psoriasis and psoriasis is
associated with the metabolic syndrome and obesity. In this regard, MΦs in visceral fat in the set-
ting of obesity are believed to contribute to an inflammatory state. MΦs are also increased in the
subcutaneous fat of obese individuals. MΦs may be activated via TLR-4 by endotoxin leaked from
the gut and by saturated fatty acids resulting from increased lipolysis in adipose tissue. Activated
MΦs may then influence the cytokine microenvironment in the subcutaneous adipose tissue and
skin by producing inflammatory cytokines such as IL-6. To test the hypothesis that activated MΦs
may skew T helper cell development toward a Th17-type, we set up an in vitro system where acti-
vated MΦs are cultivated in cultures of Langerhans cells (LCs) presenting antigen to CD4+ T cells.
C57BL/6 mice were injected intraperitoneally with 1 ml of thioglycollate broth. MΦs were harvested
after 4 days, CD11b+ MΦs were purified and 1 x 104 cells/well plated in round-bottom 96-well
plates overnight. The next day 1 x 104 LCs from C57BL/6 mice were added to the MΦs together
with 2 x 105 CD4+ T cells (obtained by negative selection) from OT-II (C57BL/6 background) mice
and the chicken ovalbumin (cOVA) fragment cOVA323-339. OT-II mice express transgenes in their T
cell receptors such that they spontaneously recognize cOVA323-339. After 48 hrs, supernatants were
assayed for cytokine content by ELISA. Addition of MΦs enhanced IL-6, and IL-17A production while
inhibiting production of IL-4. A small increase in IFNγ production was also observed in some
experiments. Stimulation of MΦs with lipopolysaccharide (LPS) prior to use further enhanced IL-
17A production. A preliminary experiment indicated that thioglycollate-elicited MΦs also enhanced
mRNA levels for IL-17A and RORγt in these cultures at 48 hrs by real-time RT-PCR. These results
suggest that MΦs (activated by thyoglycollate harvest and/or LPS exposure) enhance release of
cytokines associated with Th17 cell generation.
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Th2 cytokines from malignant T cells suppress benign Th1 responses in patients with L-CTCL
E Guenova, R Watanabe, C Schlapbach, J Desimone, A Dorosario, N Adams, DC Fisher, M Tawa,
TS Kupper and RA Clark Harvard Skin Disease Research Center and the Dana Farber/Brigham
and Women’s Cancer Center, Boston, MA
We previously reported that both benign and malignant T cells in L-CTCL patients are markedly
Th2 biased, likely contributing to the pruritus and infectious susceptibility of patients with L-CTCL.
Benign Th1 responses were enhanced in both skin and blood after depletion of the malignant T
cells with alemtuzumab, suggesting signals produced by the malignant clone may suppress benign
T cell responses. To study this question directly, we separated the malignant and benign T cells from
L-CTCL patients, cultured them separately with mature, activated autologous dendritic cells and
then assessed cytokine production by flow cytometry and multiplex cytokine analyses. In benign T
cells cultured away from the malignant clone, IL-4 production decreased (mean 22% to 8%) and
INF-γ production increased (mean 1% to 25%), suggesting that malignant T cells suppress benign
Th1 responses. In contrast, malignant clonal T cells showed no significant changes in IL-4 or INF-γ
production. To identify suppressive signals, we co-cultured T cells from healthy donors with blood
cells from L-CTCL patients. Normal T cells produced less IFN-γ (18.5% to 0.3%) after culture with
L-CTCL cells but production was restored in the presence of neutralizing antibodies to IL-4 and IL-
13 (0.3% to 20.5%). Our studies suggest that IL-4 and/or IL-13 produced by malignant T cells sup-
press Th1 responses, forcing a Th2 bias on benign T cells. In contrast, the Th2 bias of malignant T
cells is a stable phenotype likely resulting from intrinsic internal signals. Aeroderm, a small protein
antagonist of the IL-4 /IL-13 receptor, is being tested in atopic dermatitis. By inhibiting Th2 responses
and enhancing Th1 responses, IL-4/IL-13 antagonists could potentially enhance immune responses
in L-CTCL patients to both skin pathogens and the malignant T cells themselves.
599
Cigarette smoke exposure inhibits murine contact hypersensitivity reactions via the genera-
tion of Platelet-activating factor agonists
R Sahu, MJ Turner, RL Konger and JB Travers Indiana University, Indianapolis, IN
The ubiquitous environmental pollutant cigarette smoke (CS) is known to exert immodulatory effects.
CS also acts as a potent pro-oxidative stressor. Several studies including ours have characterized
the importance of various pro-oxidative stressors including UVB to inhibit host immunity and the
importance of the Platelet-activating factor (1-alkyl-2-acetyl-glycerophosphocholine; PAF), a potent
lipid mediator in this process. PAF is produced enzymatically in a tightly-controlled process. In addi-
tion, oxidative stressors can act directly on glycerophosphocholines (GPC) to produce oxidized GPC
which are potent PAF-R agonists. The present studies employed model systems consisting of PAF-
receptor (PAF-R)-expressing (KBP) and–deficient (KBM) cells and mice (wild type C57BL/6J [WT]
and Pafr-/-) to determine whether CS exposure could generate PAF-R agonists in blood and whether
it could suppress contact hypersensitivity reactions in a PAF-R-dependent manner. We show that
lipid extracts derived from the blood of CS-treated WT mice resulted in immediate intracellular cal-
cium mobilization response only in KBP cells. However, no calcium mobilization response was
detected with lipid extracts from non-smoked (sham) mice both in KBP and KBM cells. In addition,
lipid extracts only from CS-treated mice induced an increase in IL-8 secretion in KBP cells indicat-
ing that CS generates systemic PAF-R agonists. CS exposure also inhibited contact hypersensitivity
(CHS) to the allergen dinitrofluorobenzene (DNFB) selectively in WT but not in Pafr-/- mice. This
inhibitory effect of CS in WT mice were similar to those induced by the PAF-R agonist CPAF. Fur-
thermore, this inhibition of CHS by CS in WT mice was blocked by antioxidants vitamin C and N-
acetyl cysteine. These findings indicate that CS exposure induces systemic immunosuppression in
a PAF-R-dependent manner. These studies provide the first evidence that the pro-oxidative stressor
CS can modulate cutaneous immunity via the generation of PAF agonists created non-enzymati-
cally through lipid oxidation.
600
Galectin-3 modulates Th17 responses by regulating dendritic cell cytokine expression
A Fermin,1 DK Hsu,1,2 H Chen,1,2 S Wu,3 J Yu,3 L Wan,4 B Wu-Hsieh3 and F Liu1,2 1 Dermatology,
University of California, Davis, Sacramento, CA, 2 Institute of Biomedical Sciences, Academia
Sinica, Taipei, Taiwan, 3 Graduate Institute of Immunology, National Taiwan University, Taipei,
Taiwan and 4 Department of Medical Research, China Medical University, Taichung, Taiwan
Galectin-3 is a β-galactoside-binding animal lectin involved in immune regulation and cell home-
ostasis. Evidence suggests that galectin-3 controls T helper responses, although the mechanisms of
regulation have not been completely defined. Expression of the protein in dendritic cells (DC) may
play an important role. Th17 cells have emerged as critical inducers of tissue inflammation in autoim-
mune disease and important mediators of host defense against extracellular and fungal pathogens.
In the present study we investigated the role of galectin-3 in the induction of Th17 immunity through
DC. We demonstrate that galectin-3 negatively regulates Th17 polarization in DC in response to
the β-glucan curdlan or high dose LPS, two conditions that prime Th17 responses. Upon activation
of the β-glucan receptor dectin-1 or TLR4, galectin-3 deficient (gal3-/-) DC secreted higher levels
of the Th17-associated cytokine IL-23 than gal3+/+ DC. Furthermore, curdlan-stimulated gal3-/- DC
displayed higher levels of c-Rel, a transcription factor required for IL-23 expression, and lower lev-
els of active Raf-1, a serine-threonine kinase that modulates DC cytokine expression by altering
NFκB activation. In view of our previous demonstration that galectin-3 is localized to lipid rafts in
DC activated through chemokine receptor, we propose that galectin-3 may control IL-23 produc-
tion by regulation of lipid raft participation in signaling through dectin-1 and TLR-4. Compared to
gal3+/+ DC, the adoptive transfer of Candida albicans-infected gal3-/- DC into mice induced higher
Th17 responses and conferred protection against fungal infection, indicating that galectin-3 in DC
also affects T helper priming in vivo. This study identifies a role for galectin-3 in the modulation of
Th17 responses through the regulation of DC cytokines, and may be relevant in the development
of DC-based vaccines.
601
Effects of simultaneous exposure to formaldehyde and house dust mite on atopic dermatitis
in vivo
J Kim,1 M Jeong,1 M Lee2 and S Seo1 1 Department of Dermatology, Chung Ang University
College of Medicine, Seoul, Republic of Korea and 2 Department of Clinical Laboratory
Medicine, Chung Ang University College of Medicine, Seoul, Republic of Korea
Formaldehyde (FA), a typical indoor chemical pollutant emitted from indoor building materials,
has been known to be associated with development of allergic atopic diseases, such as asthma and
atopic dermatitis. However, the underlying mechanisms have not been fully elucidated. In this study,
we investigated whether FA inhalation would affect the provocation and/or exacerbation of atopic
dermatitis (AD)-like skin lesions with or without topical stimulation of Dermatophagoides farinae
(Df) in atopic-prone NC/Nga mice. Over a period of four weeks, mice were exposed daily to FA
(0.2 and 1.0 ppm) by inhalation for 6 hrs per day and/or received weekly application of 25 mg Df
ointment to both ears. FA inhalation exacerbated Df-induced manifestation of macroscopic AD-
like skin lesions and histopathological changes, including epidermal thickening and dermal infil-
tration of inflammatory cells. Interestingly, independent FA inhalation markedly increased IL-13,
IL-25/IL-17E and COX-2 mRNA expression in skin. FA inhalation also significantly elevated the level
of total plasma IgE induced by topical Df-stimulation but did not affect the Df-specific IgE level in
plasma. We also showed that FA inhalation upregulated the mRNA expression of representative
proallergic cytokines, thymic stromal lymphopoietin (TSLP), induced by Df stimulation. In the pres-
ent study, we confirmed that FA inhalation was able to exacerbate Df-induced AD-like inflamma-
tory responses. We thought that enhancement of IL-13, IL-25/IL-17E and COX-2 expression by inde-
pendent FA inhalation might be a key factor to exacerbate AD-like skin inflammation induced by
cutaneous Df stimulation. Therefore, FA inhalation may act synergistically or in combination with
cutaneous Df exposure to aggravate symptoms of AD.
602
Roles of thermosensitive transient receptor potential vanilloid (TRPV) ion channels in heat
shock induced cellular functions of human dendritic cells
AG Szöllösi,1 A Oláh,1 BI Tóth,1 F Papp,2 G Czifra,1 G Panyi2 and T Bíró1 1 DE-MTA “Lendulet”
Cellular Physiology Research Group, Department of Physiology, University of Debrecen,
MHSC, RCMM, Debrecen, Hungary and 2 Department of Biophysics, University of
Debrecen, MHSC, RCMM, Debrecen, Hungary
We have previously shown (Tóth et al, FEBS Lett, 583(10):1619-1624, 2009) that TRPV1, a multi-
modal cellular sensor first described on sensory neurons is functionally expressed on human mono-
cyte-derived dendritic cells (DCs). The goal of our current experiments was to determine the involve-
ment of TRPV1 and other thermosensitive TRPVs in mediating the heat shock induced cellular
responses in DCs. Using real-time QPCR and fluorescent immunocytochemistry we found that
DCs express TRPV1, TRPV2 and TRPV4 both at the protein and mRNA levels. In addition, we found
that heat shock (43 C for 1 hr) decreased the phagocytotic activity of DCs without affecting their
viability. This effect could not be antagonized by the application of capsazepine (TRPV1 antago-
nist) or HC067074 (TRPV4 antagonist) alone; however the suppression of phagocytosis was markedly
abrogated by the combination of these antagonists. Interestingly, the siRNA-mediated knockdown
of TRPV1 or TRPV4 had no measurable effect whereas the silencing of TRPV2 effectively abrogated
the action of the heat shock. These intriguing findings lead us to consider the novel possibility that
the TRP channels are expressed as heterotetramers on DCs (a phenomenon that has been previ-
ously described in heterologous expression systems between closely related TRPV channels). Using
immunoprecipitation followed by Western blotting we indeed found that the protein samples pre-
cipitated with a TRPV2 antibody also showed immunosignals specific for TRPV1 and TRPV4, sug-
gesting that these proteins are found in a common complexes. Taken together, our results implicate
that heat shock treatment of human DCs activates a TRPV channel complex through either TRPV1
or TRPV4, with TPRV2 acting as scaffold for the other two proteins.
603
The molecular signature of cutaneous graft-versus-host disease: IL-22 and Th2 cytokines pre-
dominate in the acute disease stage
CM Brueggen,1 I Klein,1 HT Greinix,2 W Bauer,1 Z Kuzmina,2 W Rabitsch,2 R Knobler,3 G Stingl1
and G Stary1 1 Department of Dermatology, DIAD, Medical University of Vienna, Vienna,
Austria, 2 Department of Internal Medicine I, Bone Marrow Transplantation, Medical
University of Vienna, Vienna, Austria and 3 Department of Dermatology, Division of General
Dermatology, Medical University of Vienna, Vienna, Austria
Graft-versus-host disease (GvHD) is the major clinical complication of allogeneic hematopoietic
stem cell transplantation (HCT) occurring in an acute and chronic form. It is unclear whether the
same or different pathomechanisms lead to these distinct clinical presentations. To address this issue,
we collected lesional skin biopsies of patients suffering from acute (aGvHD) (n=22) and chronic-
inflammatory (cGvHD) (n=15) GvHD as well as serial biopsies of non-lesional skin from HCT recip-
ients at different time points prior and after HCT (n=14). The cellular infiltrate was assessed by
immunofluorescent in situ analysis; interleukins and chemokines were analyzed by real-time RT-
PCR. Results obtained revealed striking differences between aGVHD and cGvHD lesions. Surpris-
ingly, we found considerably increased levels of IL-22 but not IL-17 in aGvHD skin biopsies com-
pared to samples from cGvHD patients. It further appears that the immune response occurring in
aGvHD skin lesions is skewed in the Th2 direction, as evidenced by a relative increase of Th2
cytokines (IL-4, IL-13) and chemokines (CCL17, CCL22) and, in parallel, by a downregulation of
Th1 cytokines (IFN-γ) and chemokines (CXCL9, CXCL10). CD4+ and CD8+ T-cells dominated the
inflammatory infiltrate in both, aGvHD and cGvHD lesions. Epidermal TSLP and T-cells were sig-
nificantly upregulated as early as at day 20 after HCT in non-lesional skin of subjects who had no
clinical signs of GvHD at this time point but would later develop aGvHD compared to those who
would not. Our data suggest that diverse pathomechanisms are operative in acute and chronic forms
of skin GvHD with IL-22- and Th2 cytokine-producing cells as candidate effector cells in aGvHD
lesions.
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Induction of human epidermotropic T-cell lymphoma in immunodeficient transgenic mice
after injection of CD34+ stem cells
CA Peterson,1,3 C Sun,1 P Rennert,2 G Majeau,2 A Landry2 and RW Dunstan1 1 Translational
Medicine, Biogen Idec, Cambridge, MA, 2 Discovery Immunology, Biogen Idec, Cambridge,
MA and 3 College of Human Medicine, Michigan State University, East Lansing, MI
Cutaneous T-cell lymphomas (CTCLs) represent a heterogeneous group of non-Hodgkin’s lymphoma
defined by clonal proliferation, with the most common forms characterized by epidermotropic CD4+
T lymphocytes. Little is known about the development of CTCL due to the lack of suitable animal
models. Injection of CD34+ human hematopoietic stem cells into irradiated NOD/LtSz-scid
IL2rgamma(null) neonatal mice resulted in the development of a progressive dermatologic condi-
tion with the morphologic, immunohistologic and molecular features of CTLC in a subpopulation
of the injected mice after four to five months. 70 animals with this phenotype have been studied to
date, and 32 of the animals have been molecularly characterized. The morphologic features begin
with a mild dermal infiltrate that starts to invade the isthmic region of follicles, eventually effacing
the sebaceous glands. As lesions evolve, dermal infiltrates intensify and epidermotropism becomes
marked, often accompanied by epidermal hyperplasia with hyperkeratosis. Immunohistochemistry
with human-specific antibodies defined the infiltrating cells to be CD3+, CD4+, CD8-, CD68- and
CD20-. The T-lymphocytes were also positive for the skin-homing markers CLA and CCR10. Het-
eroduplex analysis for human T cell receptor (TCR)-βA, TCR-βB, TCR-βC, TCR-γA, and TCR-γB
gene rearrangements showed oligo- and monoclonal expansion. Subsequent cloning and DNA
sequencing proved this clonal expansion and further confirmed that the lesions were caused by
human T-cells. Only animals with the CTCL phenotype demonstrated expansion of TCR genes; clonal
expansion was not identified in chimeric controls without lesions. We present this model as a unique
way to study T-cell trafficking, to define the progression and development of human CTCL from
CD34+ stem cells, and to serve as an animal model to develop therapies against this disease.
606
Generation of tumor-specific CD4+ T helper lymphocytes for immunotherapy against malig-
nant melanoma
CN Boss,1 S Kayser,2 T Feuchtinger2 and M Röcken1 1 Hospital of Dermatology, University of
Tübingen, Tübingen, Germany and 2 Children’s Hospital, University of Tübingen, Tübingen,
Germany
Novel approaches in the treatment of metastatic malignant melanoma are immunotherapies such
as adoptive T cell transfer. Those treatment strategies focused predominantly on CD8+ cytotoxic T
lymphocytes (CTLs) in the past. But strong CTL responses often did not correlate with sustained
anti-tumor protection for the patient. Recently it was shown that CD4+ T helper (Th1) lymphocytes
could be found in the tumor microenvironment, where they impaired tumor growth and angio-
genesis through cytokine signaling. IFN-γ and TNF-α were crucial. In the abscence of one of these
cytokines tumor growth was increased. Thus, Th1 lymphocytes could be more effective for
immunotherapies against metastasized malignant melanoma than CTLs. The aim of this study was
to design a protocol to generate tumor-specific CD4+, interferon-γ-producing T helper (Th1) lym-
phocytes, to characterize the generated cells and analyze their effector functions against melanoma
cells. PBMCs from healthy donors were primed with NY-ESO-1 or Survivin 15-mere overlapping
peptide mixes. After 2 weeks of stimulation with IL-2, we enriched IFN-γ producing cells with the
IFN-γ capture technique. Then cells were expanded over 2 weeks with a defined cytokine cocktail
prior to analysis. We could generate cell products with up to 3 x 109 cells, containing NY-ESO-1 or
Survivin-specific, CD4+ Th1 lymphocytes. After restimulation with the specific tumor-antigen the
generated cells produced IFN-γ and TNF-α, but not IL-10 or IL-4. These cells proliferated after
exposure to the specific tumor-antigen, but not to the control-antigen actin as shown by CFSE-
staining. Moreover, we could show that T cell cytokines can interfere with melanoma cell prolifer-
ation. In summary, high numbers of tumor-specific CD4+ T helper (Th1) lymphocytes were gener-
ated for the use in immunotherapy against metastasized malignant melanoma.
608
CD4+ T cell tolerance to melanocyte differentiation antigen TRP1
MP Rausch1,2 and KT Hastings1,2,3 1 Basic Medical Sciences, University of Arizona College of
Medicine, Phoenix, AZ, 2 Arizona Cancer Center, University of Arizona College of Medicine,
Tucson, AZ and 3 Immunobiology, University of Arizona College of Medicine, Tucson, AZ
Maintaining tolerance to skin-restricted antigens is critical for avoiding cutaneous autoimmunity. In
a mouse model of cutaneous autoimmunity, we are investigating mechanisms of T cell tolerance to
an endogenously expressed autoantigen, tyrosinase-related protein 1 (TRP1). We have shown that
gamma-interferon-inducible lysosomal thiol reductase (GILT) is essential for efficient MHC class II-
restricted processing of TRP1. In GILT-/- TRP1-specific T cell receptor transgenic mice, CD4+ TRP1-
specific T cells escape thymic deletion, but do not induce autoimmune vitiligo. GILT-/- transgenic
mice have fewer peripheral CD4+ TRP1-specific T cells compared to TRP1-deficient mice. CD4+ T
cells in GILT-/- transgenic mice have marked reduced IL-2 and IFN-γ production and a portion are
antigen-experienced. Since tolerance is only partially mediated by an increased percentage of TRP1-
specific regulatory T cells in GILT-/- mice, we sought to characterize other mechanisms that con-
strain the activity of TRP1-specific T cells. Here, we demonstrate that compared to adoptive trans-
fer of CD4+ TRP1-specific T cells from TRP1-deficient mice, fewer TRP1-specific T cells were recovered
from skin-draining lymph nodes following adoptive transfer of T cells from GILT-/- transgenic mice
into GILT-/- or GILT+/+ recipients. This result demonstrates that the decreased T cell number is not
due to differences in peripheral antigen presentation, but may be due to decreased proliferation or
increased cell death. TRP1-specific T cells from GILT-/- transgenic mice exhibited diminished anti-
gen-specific proliferation in vitro compared to T cells from TRP1-deficient transgenic mice. Sus-
ceptibility to T cell receptor ligation induced apoptosis and expression of markers of anergy and
exhaustion are under investigation. These findings suggest multiple peripheral tolerance mecha-
nisms inhibit CD4+ T cell mediated autoimmunity to an endogenously expressed cutaneous autoanti-
gen.
607
Phenotypic characterization of “signature T subsets” in the peripheral blood of psoriatic
patients
J Zhou, F Koszik, P Brunner and G Stingl Department of Dermatology, Division of Immunology,
Allergy and Infectious Diseases (DIAID), Vienna, Austria
Skin-infiltrating T helper 1 (Th1) and T helper 17 (Th17) cell subsets have been implicated in the
pathogenesis of psoriasis. However, fundamental questions where and how the activation of these
T cells occurs and how they contribute to the major pathogenic features of psoriasis have not yet
been resolved. To address this issue, we have established methods to analyze cytokine-secreting
profiles of different T cell subsets in psoriasis. A comparative assessment of peripheral blood leuko-
cytes from healthy and psoriatic individuals revealed only slightly increased numbers of circulating
IFN-γ + cells but significant elevations of IL-17+ and IL-22+ T cells in psoriatics with active and,
less so, in those with mild disease. Some of these Th1 and Th17 cells may well exhibit skin-hom-
ing properties as suggested by increased numbers of CLA (cutaneous lymphocyte antigen) + T cells
in the peripheral blood of patients with active psoriasis. Somewhat to our surprise, we found that
the percentages of circulating IL-17+ and IL-22+ T cells were increased not only in the CLA+ but
also in the CLA- memory T cell subset. Our findings underscore the importance of Th17 cells in the
immunopathogenesis of psoriasis and point to the existence of a systemic inflammatory response
in patients with severe disease.
605
CD4+ T cells regulate skin resident memory CD8+ T cells (TRM)
X Jiang,1 RA Clark,1 L Liu,1 J Seneschal,2 R Purar,1 T Tian,1 RC Fuhlbrigge1 and TS Kupper1 1
Dermatology, Brigham and Women’s Hospital, Boston, MA and 2 Dermatology, University of
Bordeaux, Bordeaux, France
The requirement of CD4+ T cell help for CD8+ T cell responses has been extensively explored in
secondary lymphoid organs using systemic infection models. Whether such help also exists in periph-
eral tissues like the skin is unknown. We recently reported that skin resident memory CD8+ T cells
(TRM) are non-recirculating and are superior to central memory CD8
+ T cells (TCM) in protecting
against re-infection. Interestingly, we also found that the acute CD8+ T cell migration into infected
skin does not require CD4+ T cell help. Further study showed that the acute protection response of
CD8+ T cells in the skin was equivalent in wild type and CD4-deficient mice. We next asked the
role of CD4+ T cells in CD8+ TRM protective responses in the skin. To our surprise, the absence of
CD4+ T cells did not impair the survival of CD8+ TRM in the skin. However, the recall response of
CD8+ TRM in previously infected skin was significantly compromised in CD4
-/- mice. The viral load
assay further showed that the recall response of CD8+ TRM was significantly compromised when
memory CD4+ T cells in the skin were depleted, suggesting that signals from memory CD4+ T cells
in the skin are delivered to CD8+ TRM locally. Taken together, these data imply that while CD4
+ T
cells are not required both for acute CD8+ T cell response and maintenance CD8+ TRM in the skin,
they do play an important role in regulating recall responses of CD8+ TRM.
609
Overexpression of TGFβ1 in murine epidermis alters skin dendritic cell homeostasis and
enhances adaptive immunity
J Mohammed,1 A Gunderson,1 L Khong,1 R Koubek,1 M Udey2 and A Glick1 1 Veterinary and
Biomedical Sciences, The Pennsylvania State University, University Park, PA and 2
Dermatology Branch, National Cancer Institute, Bethesda, MD
Epidermal expression of Transforming Growth Factor-β1(TGFβ1) in transgenic mice causes a hyper-
proliferative epidermis and skin inflammation, but recent studies show that this is not directly depend-
ent on T cells or the IL-17/IL-23 cytokine axis. In this study we used inducible transgenic mice to
examine the effects of TGFβ1 overproduction by keratinocytes on skin dendritic cells (DC). Induc-
tion of TGFβ1 in the epidermis caused an increase in number of B220- CD103- langerin- CD11b-
DC by 23-fold, B220- CD103- langerin- CD11b+ DC by 4-fold and B220+ pDC by 2-fold at 4 days
in skin draining lymph nodes (LN). Changes in DC subset percentage and numbers in the LN were
observed as early as 2 days. Skin explant and dye trafficking experiments suggested these DC orig-
inated in skin. The dermis of TGFβ1-overexpressing mice had significantly more MHCIIhi cells, includ-
ing pDC, in the absence of increased dermal DC (dDC) proliferation suggesting skin infiltration of
dDC precursors prior to LN migration. TGFβ1 induction prior to TRITC/dibutylpthalate (DBP) appli-
cation significantly enhanced the numbers of TRITC+ CD11b- and TRITC+ CD11b+ DC in regional
LN. TGFβ1 overexpression also augmented TRITC/DBP-induced LN migration of Langerhans cells
(LC) 72 hrs post-TRITC treatment, and this was mimicked by increased LC migration from skin
explants in response to exogenous TGFβ1 in vitro. Transient induction of TGFβ1 during sensitiza-
tion with DNFB led to a 1.5-fold increase in contact sensitivity responses associated with increased
central memory and IFNγ-producing CD4 T cells 5 days post-sensitization. Thus, elevated epider-
mal TGFβ1 by itself alters homeostasis of multiple cutaneous DC subsets and enhances DC migra-
tion and T cell responses to contact sensitizers. These results highlight a novel role for keratinocyte-
derived TGFβ1 in DC trafficking and the initiation of skin inflammation.
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Targeting of JAK3 prevents onset of murine alopecia areata
A Jabbari,1 Z Dai,1 L Xing,2 A de Jong,1 AM Christiano1,3 and R Clynes1,2,4 1 Dermatology,
Columbia University, New York, NY, 2 Pathology, Columbia University, New York, NY, 3
Genetics & Development, Columbia University, New York, NY and 4 Medicine, Columbia
University, New York, NY
Alopecia areata (AA) is one of the most prevalent autoimmune diseases and manifests as nonscar-
ring hair loss. The course of the disease is unpredictable, and there are currently no consistently
efficacious treatments available. The JAK3 tyrosine kinase is a downstream signaling partner of the
IL-2 receptor common gamma chain, which is shared with the IL-2, -4, -7, -9, -15, and -21 recep-
tors. JAK3 inhibitors are currently in clinical trials in humans for the treatment of acute kidney
transplant rejection and rheumatoid arthritis. Several lines of evidence support the potential effi-
cacy of JAK3 inhibitors in the treatment of AA: (1) a recently completed genome-wide association
study of AA by our group identified a number of gene-associated loci with immunological relevance,
including those for IL2/IL21 and IL2RA/IL15RA; (2) our preliminary data indicating IL-15 and IL-
15Ra are upregulated in the outer root sheath in the hair follicle of AA patients; (3) evidence that
IL-15 induces the activation, differentiation, and survival of effector CD8 T cells. We therefore
assessed the efficacy of JAK3 inhibition on the development of alopecia areata in a preclinical mouse
model. Alopecic C3H/HeJ skin grafts were transplanted onto unaffected C3H/HeJ mouse recipients
and subsequently treated with the JAK3 inhibitor tofacitinib, administered by osmotic pump. While
all control mice developed alopecia in six weeks, 0/5 mice treated with tofacitinib developed alope-
cia. Biomarker analysis, including microarray expression profiling of skin, immunohistochemical
stains, and serum marker assessments demonstrated decreased inflammatory profiles in mice treated
with tofacitinib. Our findings suggest that JAK3 inhibitors, currently in clinical development for other
autoimmune indications, may be an avenue for developing effective treatments in patients with
AA.
611
Migratory properties of skin-resident γδ T cell populations
X Jiang, M Yoo and TS Kupper Dermatology, Brigham and Women’s Hospital, Boston, MA
γδ T cells preferentially reside in epithelial tissues like skin. Dendritic epidermal T cells (DETC) in
epidermis have been studied extensively. Recently, a novel IL-17-producing γδ T cell population in
dermis was identified and demonstrated to have pivotal role in skin inflammation. Nevertheless,
their migration patterns are largely undefined. In this study, we found that almost 30% γδ T cells in
dermis, lymph nodes (LNs) and spleen are Vγ2+. This proportional distribution led us to hypothe-
size that γδ T cells may re-circulate between dermis and secondary lymphoid tissues. To test this
hypothesis, we created GFP+:GFP- parabiotic mice, and demonstrated that dermal γδT cells are con-
stantly circulating, whereas DETC are stationary and non-recirculating. We next focused on skin
homing of dermal γδ T cells and found that these γδ T cells were not diminished in lymphotoxin α-
/- mice (lacking LNs), suggesting that dermal γδ T cells can be stably maintained after seeding from
perinatal thymus. Further study revealed that dermal γδT cells express high levels of CD69, CD103,
and E- and P-selectin ligands, all of which are required for mature T cell migration to skin. How-
ever, in E- and P-selectin ligand-deficient (Fuc T IV/VII-/-) mice, dermal γδ T cells are paradoxically
increased, while DETC are remarkably diminished. Taken together, these findings may help better
define the role of γδ T cells in peripheral epithelial tissues.
612
Combined vaccine + axitinib therapy yields superior anti-tumor efficacy in a murine melanoma
model
DB Lowe,1 A Bose1 and WJ Storkus1,2,3 1 Department of Dermatology, University of Pittsburgh
School of Medicine, Pittsburgh, PA, 2 Department of Immunology, University of Pittsburgh
School of Medicine, Pittsburgh, PA and 3 University of Pittsburgh Cancer Institute, University
of Pittsburgh, Pittsburgh, PA
Axitinib (a tyrosine kinase inhibitor (TKI) inhibitor of vascular endothelial growth factor receptors)
has demonstrated modest efficacy when applied as a single agent in the setting of advanced stage
melanoma. Based on the reported ability of axitinib to “normalize” the tumor vasculature, we hypoth-
esize that combination therapy employing axitinib plus specific vaccination would promote supe-
rior activation and recruitment of protective T cells into the melanoma microenvironment, leading
to enhanced treatment benefits. Using a subcutaneous B16.OVA (M05 melanoma) model, we
observed that the combined treatment regimen yielded superior protection against melanoma growth
and extended overall survival when compared to animals receiving either single modality therapy.
Treatment benefits were associated with i.) reduction in suppressor cell (myeloid-derived suppres-
sor cells (MDSC) and Treg) populations in the tumor, ii.) activation of tumor vascular endothelial
cells, and iii.) the activation and recruitment of Type-1, vaccine-induced CD8+ T cells into tumors.
These results support the therapeutic superiority of combined vaccine + axitinib immunotherapy
and the translation of such approaches for the treatment of patients with advanced stage melanoma.
613
S100A8/A9 inhibition by genetic depletion or antibody inhibition results in opposite effects
on psoriasiform skin disease in a murine model
SM Dawes,1 D Diaconu,1 JA Wolfram,1 PA Tessier,2 TS McCormick1 and NL Ward1 1
Dermatology, Case Western Reserve University, Cleveland, OH and 2 Centre de Recherche
en Infectiologie, Centre Hospitalier de l’Université Laval, Quebec, QC, Canada
A pathogenic role for the proinflammatory calcium binding proteins S100A8/A9 in psoriasis is sup-
ported by observations that S100A8/A9 genes are located within the psoriasis PSORS4 susceptibil-
ity region and that serum and skin S100A8/A9 levels are upregulated. However the criticality and
significance of S100A8/A9 in psoriasis pathogenesis remains unclear. We previously demonstrated
highly elevated expression of S100A8/A9 (>135-fold; P<0.05) in the KC-Tie2 psoriasiform murine
model, with expression downregulated following gene repression, CsA treatment, or APC deple-
tion. To test the hypothesis that S100A8/A9 plays key cellular roles in the initiation, maintenance
and propagation of the psoriasis phenotype, we systemically treated adult KC-Tie2 mice with estab-
lished skin plaques with function blocking antibodies targeting S100A8/A9. KC-Tie2 mice treated
with S100A8/A9 antibodies had a 55% reduction in cutaneous S100A8/A9 expression (n=4; P<0.05).
Despite this decrease, the skin phenotype failed to improve and elements of the disease, specifi-
cally skin infiltrating CD11c+ dendritic cell numbers (72%) and IL-23 protein (60%; P<0.05), increased
in treated vs untreated KC-Tie2 mice. In contrast, crossing KC-Tie2 mice to S100A9-/- mice resulted
in less severe psoriasiform disease including a modest reduction in acanthosis (29%; P=0.057; n=9),
a dampened tissue specific monocyte response that included decreased TNFα, IL-6 and myeloper-
oxidase in KC-Tie2-S100A9-/- vs KC-Tie2 animals (all P<0.05) and T cell numbers and T cell-derived
cytokines, IL-17A and IL-17F failed to significantly increase compared to control animals. Taken
together, these in vivo results demonstrate that targeting S100A8/A9 using function blocking anti-
bodies is insufficient to suppress established disease and may exacerbate it; whereas decreasing
S100A9 using genetic depletion decreases the extent of disease severity in KC-Tie2 animals.
614
Tissue specific homing and antigen specificity: The majority of human peripheral blood Th9
cells are tropic for the skin
C Schlapbach, E Guenova, A Gehad, R Watanabe, J Teague, TS Kupper and RA Clark Department
of Dermatology, Brigham and Women’s Hospital / Harvard Medical School, Boston, MA
Most infections occur through epithelial barrier tissues and recent findings in mice suggest these
tissues are progressively colonized by memory T cells specific for pathogens encountered through
that tissue. To investigate this issue in humans, we studied the antigen-specificity and cytokine pro-
file of human tissue-tropic and tissue-resident memory T cells. We stimulated human skin-homing
(CLA+ ) and gut-homing (α4β7+ ) memory T cells from blood with a broad panel of viral, bacterial,
and fungal pathogens. We observed preferential responses of skin-tropic CLA+ T cells to skin pathogens
(e.g. S. epidermidis, C. albicans) and gut-homing α4β7+ T cells to GI pathogens (e.g. rotavirus, S.
typhimurium), in agreement with the hypothesis that T cells in a particular tissue site are specific
for infections encountered through that tissue. Intriguingly, cytokine analysis of the pathogen stim-
ulated T cells revealed that IL-9 was only produced by CLA+ T cells stimulated with Candida albi-
cans but not by α4β7+ or CLA-/α4β7- T cells. No other pathogens elicited significant production of
IL-9 in any subpopulation of T cells. Furthermore, TGF-β induced a population of T cells with a Th9
phenotype (IL-9+/IL-4-/IL-17-/IFN-γ-) in skin tropic CLA+ but not CLA- memory T cells. To determine
if the skin-homing Th9 cells found in blood are also present in skin, we analyzed tissue-resident T
cells isolated from healthy skin and gut. Skin-resident T cells contained a reproducible and distinct
population of Th9 cells whereas gut-resident T cells did not. These results suggest that human Th9
cells distinctly home to and reside within the skin and that many are specific for the cutaneous
pathogen C. albicans. Thus, our findings establish a link between tissue-specific imprinting of hom-
ing potential and pathogen-specific imprinting of cytokine profiles during the course of T helper
differentiation.
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Stage I primary cutaneous SCCs from solid organ transplant recipients show increased IL-22
producing CD8+ T-cells
S Zhang,1 H Fujita,2 JS Pettersen,3 MJ Bluth,3 H Mitsui,2 JG Krueger,2 D Felsen4 and JA Carucci1 1
Dermatology, NYU Langone Medical Center, New York, NY, 2 Laboratory for Investigative
Dermatology, The Rockefeller University, New York, NY, 3 Dermatology, Weill Cornell Medical
College, New York, NY and 4 Urology, Weill Cornell Medical College, New York, NY
Solid-organ transplant recipients (OTRs) have a 100-fold increased risk of developing cutaneous
squamous cell carcinomas (SCC) compared to non-OTRs, and are susceptible to higher rates of
recurrence and metastasis. To better understand the tumor microenvironment of transplant-associ-
ated SCC (TSCC), we compared TSCC (n=10) to SCC in immunocompetent patients (n=10) and
normal skin (n=5). Immunohistochemical staining for CD3, CD8 and Foxp3, a marker of regulatory
T-cells (T-regs), were carried out on tissues obtained at Mohs surgery. We also performed intracel-
lular cytokine staining for IFN-γ and IL-22 on T-cells isolated from SCC (n=20) and TSCC (n=12), as
IL-22 is known to induce keratinocyte proliferation and IFN-γ augments anti-tumor immunity. We
found SCC and TSCC are both associated with significantly higher numbers of CD3+ and CD8+ T-
cells compared to normal skin (p<0.05). Foxp3+ T-regs are also significantly increased in the tumor
microenvironment (TSCC 343.2 ± 4.9 cells/mm2 and SCC 437.2 ± 7.0 cells/mm2 vs. none in nor-
mal skin; mean ± SEM, p<0.01). Interestingly, TSCC contained a higher proportion of T-regs to
CD8+ T-cells compared to SCC (TSCC 0.973 ± 0.22 vs. SCC 0.453 ± 0.05, p<0.05). Furthermore,
intracellular cytokine staining showed a lower percentage of IFN-γ producing CD4+ T-cells (TSCC
15.1% ± 2.3 vs. SCC 25.1% ± 3.2, p<0.05) but a higher percentage of IL-22 producing CD8+ T-cells
in TSCC compared to SCC ex vivo (TSCC 4.2% ± 1.2 vs. SCC 2.2% ± 0.75, p<0.05). A greater num-
ber of T-regs and fewer IFN-γ producing T-cells may attenuate cytotoxic T-cell function in TSCC.
Increased levels of IL-22 could accelerate tumor growth. These results may explain the rapidly pro-
liferative nature of TSCC, and IL-22 may be an attractive candidate for targeted therapy for SCC in
transplant patients.
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Resident memory T cells are much more effective than central memory T cells in protection
against viral skin infection
X Jiang, RA Clark, L Liu, AJ Wagers, RC Fuhlbrigge and TS Kupper Brigham and Women’s
Hospital/Harvard Medical School, Boston, MA
Viral infection through skin results in durable immunologic memory mediated in large part via mem-
ory T cells, including effector memory T cells (TEM) and central memory T cells (TCM). The former
can reside in epithelial tissues as resident memory T cells (TRM), while the later typically re-circu-
late between blood and secondary lymphoid organs. The relative roles of skin TRM and TCM in immune
protection had yet to be determined. To address this question, we infected antibody-deficient (μMT)
mice via skin with VACV, and analyzed both skin and lymph nodes 30 days later. Skin contained
VACV-specific TRM that had cell surface markers of TEM, while lymph nodes and blood contained
VACV specific TCM. Next, we created parabiotic mouse pairs between infected and uninfected mice,
and determined that TCM equilibrated after two weeks, while TRM never crossed from infected to
uninfected mice. We then created new parabiotic pairs as above, and separated them after 4 weeks
of parabiosis. The uninfected mice contained TCM but not TRM (TCM mice), while the previously infected
mice contained both TRM and TCM (TRM mice). We challenged both TCM and TRM mice through skin
with VACV, and measured viral load by PCR at 6 days. TRM mice rapidly cleared the infection by 6
days. However, TCM mice still had considerable viral load at both 6 days and 14 days (10
3 fold higher
than TRM mice), and did not completely clear VACV skin infection until day 26 after infection. These
data suggest that T cell mediated immune memory to viral infection resides largely within popula-
tions of TEM that live in tissue (TRM), and that TCM function as cells that can potentially augment, but
not replace, TRM -mediated immunity.
618
Interleukin 9 exerts its tumor inhibitory effects via mast cell activation
R Purwar, C Schlapbach, S Xiao, HS Kang, AM Jetten, R Fuhlbrigge, VK Kuchroo, RA Clark and
TS Kupper Brigham and Women’s Hospital/Harvard Medical School, Boston, MA
Interleukin 9 (IL-9) is a cytokine that acts through a γ-chain common to receptors for IL-2, IL-7, IL-
15, and IL-21. We have shown that IL-9 plays a role in tumor immunity in a B16 melanoma model;
however, the mechanism for this effect has not been clear. Both administration of IL-9, and transfer
of in vitro polarized Th9 cells, can reduce tumor growth. Using a blocking antibody to IL-9, we can
demonstrate that tumor growth is enhanced in normal mice. Strikingly, we also show that the pro-
tective effect of Th9 T cells is abrogated in the presence of blocking antibody. To further dissect the
mechanism of IL-9 in tumor inhibition, we implanted B16 melanoma cells in the skin of mice that
lacked an adaptive immune system (Rag1-/-). The protective effect of IL-9 was not diminished. How-
ever, the protective effect of IL-9 was completely abrogated in mast cell deficient mice (Kit W-sh),
suggesting a role for these known targets of IL-9 in tumor immunity. To determine whether this
effect is could be generalized to other cancers, we studied a second very different tumor—Lewis
Lung Carcinoma (LLC-1). Administration of IL-9 to mice bearing LLC-1 tumors also slowed tumor
growth. Finally, we injected LLC-1 into the skin of mast cell deficient mice, and found that IL-9 had
no tumor inhibitory growth in this setting. We conclude that IL-9, a product of a subset of activated
T cells, exerts its anti-tumor effect primarily through innate immune pathways, and that mast cells
are critical for this effect. While Th9 T cells have recently been identified in humans, the role of IL-
9 in human tumor immunity has yet to be determined.
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Dissolvable microneedle arrays enable delivery of live adenovectors to the skin for cuta-
neous transduction and genetic immunization
G Erdos,1 C Donahue,1 J Zhang,1 A Gambotto,2 BO Ozdoganlar3 and LD Falo1 1 Department of
Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2 Department of
Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA and 3 Department of
Mechanical Engineering, Carnegie Mellon University, Pittsburgh, PA
Developments in technology that would enable efficient skin transfection would have a significant
impact on gene therapy efforts, including efforts to develop skin targeting gene vaccines. To meet
this challenge, we have developed novel dissolving microneedle arrays (MNAs) to specifically deliver
live adenovectors to the skin. The MNA design and fabrication process we have developed results
in adenovectors containing MNAs (Ad-MNA) that effectively maintain and preserve adenovector
viability, and enable efficient delivery of infectious vector to the skin. Specifically, we show that
adenovectors embedded in MNAs remain viable and infectious, and that Ad-MNAs retains infec-
tivity for up to 1 year. Further, topical application of Ad-MNAs to mouse skin in vivo and living
human skin explants results in transduction of skin cells and expression of transgenic antigens as
detected by fluorescent microscopy and qPCR analysis of the transgene products. Furthermore, mice
immunized topically with Ad-MNA encoding an SIV gag antigen generated potent antigen specific
immune responses. Taken together, our results demonstrate the capacity of MNAs to preserve and
deliver adenovectors to the skin for skin transduction and genetic immunization. This novel tech-
nology platform may enable a broad range of topical skin-targeted gene therapy approaches and
the clinical deployment of topical adenovectored genetic vaccines.
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In situ activation of human skin resident T regulatory cells by autologous langerhans cells
J Seneschal, RA Clark and TS Kupper Brigham and Women’s Hospital/Harvard Medical School,
Boston, MA
Human skin contains abundant populations of resident memory T cells (TRM), including a popu-
lation of regulatory T cells (Treg). Human skin also contains diverse populations of dendritic cells
that can present antigen very efficiently to these TRM. It was previously demonstrated that in vitro,
autologous Langerhans Cells (LC), but not other DC, can induce proliferation in a subset of TRM,
and that these TRM are almost exclusively Treg, by both functional and phenotypic criteria. To deter-
mine whether this proliferation depended upon antigen presentation, we used blocking antibodies
to Class I and II MHC, as well as CD1a. Only Class II blocking antibodies could inhibit LC induced
Treg proliferation. We further used blocking antibodies to HLA-DR, DP, and DQ, and found that the
inhibitory affect was mediated by HLA-DR. Finally, we asked whether we could see evidence for
LC activation of Treg in intact human skin. Using multicolor immunofluoresence, we were able to
show FoxP3+ T cells in apposition to CD1a LC in epidermis, and could show that a subset of these
T cells expressed the proliferation antigen Ki67. Taken together, these data suggest that in normal
uninflamed skin, LC may function to constitutively activate resident Treg, providing some insurance
against inadvertent or excessive activation of other TRM by commensal organisms or self antigens.
617
Global TRM mediated immune protection in skin after single or multiple skin infections
X Jiang, L Liu, RA Clark and TS Kupper Brigham and Women’s Hospital/Harvard Medical
School, Boston, MA
Vaccinia virus (VACV) infection of skin leads to long lived populations of VACV-specific memory
CD8 T cells that reside in skin (TRM) and mediate protection against subsequent VACV infection. We
assessed the accumulation of TRM at the site of infection, as well as at distant skin sites. TRM accu-
mulated most efficiently at the site of infection, but were also readily detectable at distant skin sites
at all time points measured. We next compared the capacity of TRM at the previously infected site,
versus a distant skin site, to eliminate VACV after a skin challenge infection. Mice were challenged
30 days after the initial VACV infection through a new skin infection at the same site or a distant
site. At 6 days, viral load was measured by PCR. At this time point, mice completely cleared the
same site challenge (viral load undetectable), but also cleared a distant site skin challenge only
slightly less efficiently (viral load ~ 101). By contrast, naïve mice had skin viral loads of 105-106 at
this time point. This suggests that skin infection results in long term TRM memory distributed through-
out the entire skin surface. To determine whether multiple skin infections led to further accumula-
tion, mice were either infected once or multiple times at different sites. VACV specific CD8 T cells
(TRM) were measured in the left ear (never-infected skin) after 30 days. While TRM were measurable
in the never infected skin of once-infected mice, their absolute numbers increased more than 6-
fold after multiple distant skin infections. This suggests that multiple encounters with an infectious
organism results in enhanced accumulation of TRM, suggesting a mechanism for the etiology of the
abundant TRM seen in the skin of adult humans.
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Flt3L-dependent Langerin(-) CD11b(-) DC are efficient skin-resident antigen presenting cells
JS Dobrin,1,2 R Feder,1 C Cheong,1 A Teixeira,1 RM Steinman1 and N Anandasabapathy1 1
Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY
and 2 Department of Medical Education, Mount Sinai School of Medicine, New York, NY
Skin derived dendritic cells (DC) are potent antigen presenting cells, playing a critical role in the
initiation of adaptive immune responses. Murine skin contains 5 phenotypically distinct Dendritic
Cell (DC) subsets in the steady state that continuously migrate to the skin draining lymph node
(LN). Langerin(-)CD11b(-) dermal DC are a low-frequency, heterogeneous, relatively uncharacter-
ized skin DC subset, comprising less than 20% of all migratory DC in the steady state LN. In this
study, we build on the observation that Langerin(-)CD11b(-) DC are both Fms-like tyrosine kinase
3 ligand (Flt3L) dependent and strongly Flt3L responsive, which may relate them to CD11b (low)
classical DCs. DC harvested from lymph nodes draining FITC painted murine skin, and from media
following 72 hour incubation of ex vivo murine ears (“crawlouts”) demonstrate the cutaneous ori-
gin of this subset. CCR7 knockout mice, lack DC migration from the skin to the draining LN and
accumulate Langerin(-) CD11b(-) dDC in the skin. Langerin(-)CD11b(-) DC expand locally in the
skin, become 60-70% CD24(+) to Flt3L, and present antigen by mixed leukocyte reaction with equal
efficiency to classical CD8 alpha (+) DC. This work suggests the previously overlooked Langerin(-
)CD11b(-) subset of dDC may be an attractive target for dermally delivered vaccine antigens.
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Poly(dG) particulate vaccines target and activate skin antigen presenting cells to induce potent
immunity in vivo
H Toussaint, JT Narciso, G Erdos, AT Larregina, C Donahue and LD Falo Department of
Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA
The skin microenvironment is readily accessible and rich in antigen presenting cells (APCs), mak-
ing it a preferred target site for vaccination. The development of effective strategies to target and
activate skin APCs in vivo is a critical challenge for vaccine design. Access and engagement of mul-
tiple resident and migratory dendritic cells (DCs) subsets in tissue by the vaccine may be critical to
optimize immune responses. We have designed an APC targeting strategy based on simple and direct
coupling of Poly(dG) oligo deoxynucleotides to protein antigens. Our results suggest that this con-
jugation strategy induces spontaneous aggregation of antigen into particulate complexes with APCs
targeting features and intrinsic adjuvant function. In comparison to soluble antigen, Poly(dG) par-
ticulates formed by conjugation of Poly(dG) and OVA (Poly(dG)-OVA) bind to the cell surface of
DCs with higher affinity, are rapidly and more efficiently internalized, and follow distinct intracel-
lular processing pathways. Functionally, Poly(dG)-OVA particulates are both efficiently presented
to class II-restricted T cells, and cross-presented to class I-restricted T cells. Further, in vivo immu-
nization by intradermal injection of Poly(dG) particulates induce both cellular and humoral anti-
gen specific immunity. Extending our findings to human skin, we show that intradermal injection
of Poly(dG) particulates result in efficient uptake by human skin DCs, preferentially dermal CD14+
DCs that also acquire potent T cell stimulatory functions. Taken together these results suggest that
Poly(dG) particulate antigens target and activate human skin APCs, and provide a platform for the
development of more effective skin targeted vaccines.
623
Identification of soluble immunophilin FKBP52 as a potent macrophage (Mφ) activating fac-
tor
M Pedler,1 CC Striebich,2 EZ Eisenmesser,3 LM Moldawer,4 M Fujita,1 DA Norris1 and CK Edwards1
1 Dermatology, University of Colorado Denver, Anschutz Medical Campus, Denver, CO, 2
Rheumatology, University of Colorado Denver, Anschutz Medical Campus, Denver, CO, 3
Biochemistry and Molecular Biology, University of Colorado Denver, Anschutz Medical
Campus, Denver, CO and 4 Surgery, University of Florida, Gainesville, FL
Autoimmune skin diseases cause tremendous human suffering. TNFα inhibitors block innate and
adaptive immunity, and deliver partial efficacy. Numerous adverse effects of anti-TNFα therapies
are routinely observed. Selective blockade of autoreactive T cells has not been sufficiently met by
anti-cytokine biologicals. FKBP52 (Hsp56; PPIase), a known target of FK506 and rapamycin, is coded
by the FKBP4 gene, and is a member of the immunophilin protein family of chaperone molecules
with cis-trans prolyl isomerase activity. We demonstrate that intracellular FKBP52 is upregulated
upon T cell activation and translocates to the T cell surface by physiologically binding to EMMPRIN
(CD147); this complex facilitates T cell-mediated, Mφ cytokine production in a cell-cell contact
manner. We also demonstrate that FKBP52 exists as an extracellular molecule and rhFKBP52 acti-
vates Mφ. THP-1 or PBMC-derived Mφ previously treated (24h) with priming agents PMA (100nM),
MCSF1 (10ng/mL) or GMCSF (2ng/mL), and then treated (24h) with rhFKBP52 (1–1000 ng/ml), results
in potent Mφ activation. Cytokine (TNFα, IL1β, IL6, IL8, IL32γ) measurements from Mφ supernatants
show that rhFKBP52 significantly (p<0.001) increases cytokines in comparison to untreated Mφ.
Each priming agent used in combination with rhFKBP52 results in significant (p<0.001) Mφ activa-
tion when compared with rhFKBP52-treated Mφ alone. Polymyxin B (100ng/ml) added to rhFKBP52
does not reverse its Mφ-activating effects. Using immunoprecipitation, we purified native FKBP52
from RA patient synovial fluids and human Mφ cell culture supernatants. These results suggest that
FKBP52 exists as intracellular and excellular forms, and may function as a key immune mediator
in the coordinated control of innate and adaptive immune responses.
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Clues for Epstein-Barr virus reactivation with the subsequent outbreak of immune responses
in skin lesions of hypersensitivity to mosquito bites
K Iwatsuki,1 T Yamamoto,2,1 Y Hirai,1 T Miyake,1 K Tsuji,1 D Suzuki,1 T Hamada1 and S Morizane1
1 Dermatology, Okayama University Graduate School of Medicine, Dentistry, and
Pharmaceutical Sciences, Okayama, Japan and 2 Dermatology, Kawasaki Hospital, Kawasaki
Medical School, Okayama, Japan
Epstein-Barr virus (EBV)-associated hypersensitivity to mosquito bites (HMB) is characterized by
ulceronecrotic skin lesions as well as infectious mononucleosis-like systemic symptoms. Our pre-
vious study indicates that EBV-associated hydroa vacciniforme (HV) is associated with increased
numbers of EBV+ γδT cells, while HMB is pathogenically related to EBV+ NK cells. We have hypoth-
esized that the induction of lytic-cycle EBV infections in the mosquito-bitten sites may induce severe
host immune responses. In the present study, molecular markers for both lytic- and latent-cycle
EBV infections were assayed in cutaneous lesions, peripheral blood samples, and EBV+ T or NK
cell lines in both HMB and HV. Inflammatory cell infiltrates and circulating EBV+ cells were exam-
ined by immunophenotyping and in situ hybridization. We found that 31 of 33 (93.9%) HV lesions
were composed of EBV+ T-cells and reactive EBV- cytotoxic T-lymphocytes (CTLs), without signifi-
cant CD56+ cell infiltration, whereas many CD56+ cells were present in 8 of 9 (88.9%) HMB lesions
associated with massive infiltration of EBV- CTLs and NK cells. Although circulating EBV+ NK cells
showed the latency I/ II pattern of EBV infections, 3 of 5 (60%) HMB skin lesions exhibited the pres-
ence of lytic-cycle infection-related EBV gene products, BZLF-1 mRNA. EBV+ NK cell line cells
established from HMB patients produced BZLF-1 mRNA after treatments with phorbol 12-myristate
13-acetate (PMA) or TNF-α and EBV virion-derived DNA was detected in the supernatants of PMA-
stimulated NK cell line cells. These observations indicate that EBV reactivation is primarily induced
in EBV+ NK cells infiltrating in the mosquito-bitten sites, followed by the outbreak of secondary CTL
responses against newly generated EBV antigens.
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Reduced myeloid-derived suppressor cell function is associated with interferon therapy of
cutaneous T-cell lymphoma. 
MK Schowalter, OE Akilov, LD Falo and LJ Geskin Dermatology, University of Pittsburgh School
of Medicine, Pittsburgh, PA
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature cells of
myeloid lineage with suppressive function. Increases in MDSCs have been associated with immuno-
suppression and decreased anti-tumor effector activity in numerous cancers. While the mechanisms
of MDSC immunosuppression are unclear, MDSCs are thought to mediate T-cell effector suppres-
sion via increases in intracellular reactive oxygen species (ROS) and serum arginase I (ARG), both
of which can serve as surrogate markers of MDSC function. Type I interferons (IFN) have been shown
to promote the maturation of myeloid progenitor cells, including immature MDSC, and MDSC
maturation has been associated with reduced immunosuppressive function. As IFN therapy can have
a significant clinical benefit in cutaneous T-cell lymphoma (CTCL), we hypothesized that IFN may
work at least partially through induction of MDSC maturation that reduces immunosuppression. We
sought to evaluate the effect of interferon alpha-2b (IFNa2b) therapy on the number and function
of MDSC in CTCL patients. Patients for whom IFN therapy was indicated were enrolled in this study
per IRB protocol. Peripheral blood samples were obtained prior to initiation of IFN therapy and
sequentially during therapy. We found that although IFN therapy did not result in reduction of
absolute numbers of peripheral blood MDSCs, clinical responses were associated with substantial
and significant reductions in intracellular ROS in MDSCs and decreases in serum ARG, indicative
of decreased suppressive function. These findings suggest that in CTCL patients a positive response
to IFN may be mediated in part through the suppression of MDSC function, potentially defining a
novel target for CTCL therapy.
626
Treatment with Ruxolitinib, an orally bioavailable JAK1/2 inhibitor, prevents the onset of
alopecia areata in C3H/HeJ mice
Z Dai,1 L Xing,4 A Jabbari,1 A de Jong,1 AM Christiano1,3 and R Clynes2,4 1 Dermatology,
Columbia University, New York, NY, 2 Medicine, Columbia University, New York, NY, 3
Genetics & Development, Columbia University, New York, NY and 4 Microbiology and
Immunology, Columbia University, New York, NY
Alopecia areata (AA) is a common organ-specific autoimmune disease marked by lymphocytic infil-
trates around hair follicles. Aberrant expression of Th1 cytokines (IL-2, INF-γ and IL-12), IL-1and
TNF-alpha have been detected in AA. INF-γ is one of the crucial cytokines which is thought to con-
tribute to the pathogenesis of AA. Binding of INF-γ to its receptor induces oligomerization of the
receptor and activation of the receptor-associated Janus kinases 1 and 2 (JAK1 and JAK2) for down-
stream signal transduction. Inhibiting INF-γ signal transduction can be achieved by blocking JAK1
and JAK2. An orally bioavailable inhibitor of JAK1 and 2, Ruxolitinib, has been reported to be effec-
tive in murine models of arthritis and clinically approved for the treatment of myelofibrosis, a JAK2-
mediated hematological disorder. To test whether Ruxolitinib can prevent or delay the onset of AA,
we have utilized a mouse model of AA by grafting of alopecic skin from C3H/HeJ mice with AA-
like hair loss onto unaffected C3H/HeJ mice. Grafted mice were given a dosage of 60mg/kg Rux-
olitinib or methylcellulose by oral gavage daily. After 12 weeks of treatment, none of the Ruxoli-
tinib-treated mice exhibited onset of AA, whereas 80% of control mice developed AA with an average
40% body hair loss. Biomarker analysis revealed that the microarray expression profile of genes
downstream of INF-γ such as the chemokine genes CXCL9, CXCL10 and CCL5 are significantly
decreased in Ruxolitinib-treated mice. Immunohistochemical staining of skin biopsies shows that
Ruxolitinib-treated mice have a striking decrease in MHC-I, MHC-II, H60 and Rae-1 expression.
Furthermore, there are fewer CD8+ T and CD4+ T cells infiltrate around hair follicles than in con-
trol mice. Collectively, our results indicate that JAK1 and 2 signaling pathway may be an attractive
therapeutic target in the treatment of AA.
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Lipids from human epidermis can function as antigens for CD1a-restricted T cells
A de Jong,1 T Cheng,2 S Huang,2 AG Kasmar,2,3 V Pena-Cruz,4 J Altman5 and D Moody2,3 1
Dermatology, Columbia University Medical Center, New York, NY, 2 Rheumatology,
Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, 3 Harvard Medical
School, Boston, MA, 4 Dana Farber Cancer Institute, Boston, MA and 5 Emory Vaccine Center,
Atlanta, GA
CD1a is a MHC class I-like antigen presenting molecule that presents lipid antigens to T cells and
is highly expressed on human epidermal Langerhans cells. We recently identified a subset of human
αβT cells that is activated by CD1a, and many of these T cells share characteristics with Th22 cells,
including the expression of the skin homing chemokine receptors CCR4 and CCR10, the aryl hydro-
carbon receptor, and the production of Interleukin-22, a cytokine involved in skin homeostasis and
immunity. These CD1a-autoreactive T cells are detected in peripheral blood and in the skin under
non-inflammatory conditions, suggesting a normal physiological role for these cells in the tissue.
Self reactivity is a key feature of CD1-restricted T cells and is exemplified by their ability to recog-
nize endogenous lipid antigens. The specific natural “self” lipid antigens presented by CD1 mole-
cules have remained an open question in the field. To identify the structures of CD1a presented
antigens, we used a cell-free system with plate-bound recombinant CD1a protein and screened lipid
extracts from various human tissues for recognition by a CD1a-autoreactive T cell line. This revealed
that human epidermis is enriched for hydrophobic stimulatory lipid antigens, which lack the
hydrophilic head groups generally seen in CD1 antigens. The skin-specific accumulation of these
natural CD1a antigens and their co-localization with CD1ahigh Langerhans cells in human epi-
dermis suggests a mechanism of local stimulation of CD1a-autoreactive T cells. The presence of
natural CD1a antigens in skin indicates that, in addition to barrier function, human epidermal
lipids can also play a role in skin immunity and homeostasis
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microRNAs regulate epidermal Langerhans cell cross-presentation
Q Mi,1,2,3 Y Xu,1,2 R Qi1,2 and L Zhou1,2,3 1 Henry Ford Immunology Program, Henry Ford
Health System, Detroit, MI, 2 Dept of Dermatology, Henry Ford Health System, Detroit, MI
and 3 Dept of Internal Medicine, Henry Ford Health System, Detroit, MI
Langerhans cells (LCs) are skin-residential dendritic cells (DCs) with a life cycle distinct from other
types of DCs and place very important roles in skin immunity and tolerance. MicroRNAs (miRNAs),
evolutionarily conserved small non-coding RNAs that repress target genes, regulate immune cell
development and function. Recent studies from our laboratory and others indicated that miRNA
deletion in DC-lineage interrupts the homeostasis and function of epidermal LCs with normal con-
ventional DCs, suggesting that miRNAs are required for LC development and function. However,
the roles of individual miRNAs in regulating LC development and function are still completely
unknown. miRNAs miR-150 and miR-223 are highly expressed in mature lymphocytes and myeloid
cells, respectively. We have found that miR-150 and miR-223 are also expressed in LCs and the
expression of miR-150 is significantly down-regulated during in vitro LC maturation. Using miR-
150 and miR-223 knockout mouse models, we have found that lack of miR-150 or lack of miR-223
does not disturb the development, maturation, migration and phagocytic capacity of epidermal LCs.
However, lack of miR-150 significantly reduces the capacity of LCs to cross-present a soluble anti-
gen to antigen-specific CD8+ T cells, while lack of miR-233 significantly increases the capacity of
LC cross-presentation. Thus, our data indicate that miR-150 and miR-223 are not required for LC
development, but differentially regulate LC cross-presentation.
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Assessment of the number of T cells responding to a given hapten using deep TCR sequenc-
ing
OF Gaide,1,2 V Philippe2 and TS Kupper1 1 Dermatology, Brigham and Women’s Hospital,
Harvard Medical School, Boston, MA and 2 Pathology-Immunology, Geneva University,
Geneva, Switzerland
How many T cells actually recognize a given hapten in vivo? Surprisingly, there is no precise
answer to this basic question in the literature. We often state that TCR rearrangement results in a
near-infinite number of clones potentially covering any non-self antigen. In fact current estimates
place it closer to 10E19, still very high. However, high throughput sequencing of the TCR reveals
that humans carry a relatively low number of distinct T cell clones. The number of different TCR beta
chains in the entire blood compartment is for example estimated at only 3-4 millions. The number
drops by an order of magnitude for memory T cells. This suggests that the number of clones that
react to a given hapten is in fact limited. Is it 10 different clones, 100, 1000 or more? To provide an
answer to this question, we have studied the extent of the TCR beta chain repertoire in normal and
DNFB sensitized mice, using high throughput sequencing of the TCRbeta chain (Adaptive
Immunoseq). This technique allows us to determine the number of TCR that are significantly enriched
following repeated DNFB exposure (0 exposure, 2 exposure, 5 exposure) within the skin and cor-
responding lymph nodes of C57Bl/6 mice. To our knowledge, this is the first study making advan-
tage of modern sequencing techniques to provide a comprehensive analysis of the T cell repertoire
for a given hapten.
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Subcutaneous protein antigen immunization with epicutaneous Toll-like receptor 9 agonist
induces protective immune responses against influenza A viral infection
W Cheng,1 A Plumb,2 N Abraham2 and JP Dutz1 1 Dermatology and Skin Science, University of
British Columbia, Vancouver, BC, Canada and 2 Microbiology and Immunology, University of
British Columbia, Vancouver, BC, Canada
Humoral and cell-mediated immune responses are critical to combat viral infections. This study
presents a novel delivery method of vaccines to enhance both humoral and cell-mediated immune
responses by combining protein antigen with a Toll-like receptor 9 agonist (CpG ODN1826) admin-
istered through the subcutaneous and epicutaneous route, respectively. This immunization regimen
was able to elicit strong antigen-specific humoral and cell-mediated immune responses. These data
demonstrate that prime-boost immunization of soluble OVA protein with CpG ODN1826 enhanced
rapid OVA-specific CD8+ T cells production as well as long-lasting OVA-specific CD8+ memory T
cells and OVA-specific IgG2c antibodies. Furthermore, these responses conferred protection against
intranasal challenge with recombinant influenza A virus expressing the OVA257-264 peptide (PR8-
OVA). Together, these results demonstrate that administering a Toll-like receptor agonist epicuta-
neously as adjuvant augments both arms of protective immune responses. This vaccination regi-
men has great potential to be implemented in human vaccinations to improve effectiveness of the
vaccines without reformulation to combat viral infections.
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Effective immunoprevention against chemical carcinogenisis is induced by genetic immu-
nization vectors that selectively expand mutant H-ras-specific CD8 T cells
T Nasti, K Rudemiller, G Twitty, H Kim, Y Tsuruta, M Athar, C Elmets and L Timares Dermatology,
University of Alabama at Birmingham, Birmingham, AL
T cell-mediated immune responses induced by polyaromatic hydrocarbons (PAHs) are associated
with resistance to tumorigenesis by those agents. The carcinogenic PAH 7,12-dimethylbenzan-
thracene (DMBA) results in a characteristic point mutation, Q61L, in the H-ras oncogene (H*ras).
We tested the hypothesis that a vaccine designed to focus T cell specific immunity to the H*ras epi-
tope would eliminate tumor initiating cells harboring DMBA-induced mutations and protect against
carcinogenesis. Plasmid- and lentivector-based vaccines were engineered to favor H*ras epitope
presentation to CD8 T cells. H*ras-specific DTH and CTL responses were detected in mice immu-
nized with vectors encoding Ub/H*ras/EGFP, but not control Ub/WT H-ras/EGFP chimeric genes.
H*ras immunized mice generated increased numbers of IFN producing CD8 T cells following chal-
lenge with DMBA, indicating that H*ras expressing cells were recognized. Immunized A/J and
C3H mice were subjected to DMBA/TPA chemical carcinogenesis for 24 weeks. Both mouse strains
were specifically protected by Ub/H*ras/EGFP gene vaccination, which effectively blocked tumor
initiation (55% fewer; p=0.004) and growth (75% smaller; p=0.02) in comparison to tumor devel-
opment in control cohorts. H*ras mRNA expression was selectively abrogated in tumors from mice
vaccinated with H*ras but not control vectors, providing evidence that immuno-editing plays a
protective role. No significant differences in tumor histopathology profiles were observed. In con-
trast to tumors from control conhorts, tumors from H*ras immunized mice demonstrated a dimin-
ished capacity to grow explant cultured cell lines. Keratin 1 staining was observed in all but the
H*ras immunoeditied tumor line. These results support further development and study of epitope
focused vaccines for immunoprevention of cancer.
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The discovery of the importance of skin resident memory T cells (TRM) in contact hypersen-
sitivity suggests that current molecular/mouse models may not be informative of human dis-
ease
OF Gaide and TS Kupper Dermatology, Brigham and Women’s Hospital, Harvard Medical
School,, Boston, MA
Current murine models of contact hypersensitivity (CHS) are based on obsolete models of the immune
system and may be misleading. To back up this provocative assertion, we provide evidence in mice
that contact eczema relies principally on TRM, which can best be studied using local long-term sen-
sitization/challenge regimens. Importantly, our model more closely parallels what we routinely see
in our patients. Specifically, we found that repeated local sensitization induces an immune response
that is more pronounced at the local site of sensitization than at distant sites. This site predilection
persists for months, and is due to TRM. Indeed, blocking T cell migration out of the lymph nodes,
resulting in complete blood T cell depletion, has no impact on the local response. Conversely, it is
possible to use this type of inhibition to block i) low-level sensitization inducing central memory T
cells (TCM), and ii) determine the rapidity of the colonization of TRM to the skin. Importantly, para-
biotic mice that share TCM but not TRM confirm that contact eczema is mediated primarily by tis-
sue resident memory cells. Our findings sheds new light on clinical findings such as: i) the difficulty
to desensitize patients systemically, as the target T cells are not circulating but instead TRM,and ii)
the occurrence of negative patch test at distant sites (ie back) compared to the disease site (hands
or else). These observations will permit the generation of new CHS animal models that more closely
approximate human disease.
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IL-17A is involved in P. acnes-induced inflammation
GW Agak,1 M Qin,1 J Nobe,1 M Kim1,2 and J Kim1,3 1 Division of Dermatology, Department of
Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, 2 Department of
Dermatology, Dankook Medical College, Cheonan, Republic of Korea and 3 Department of
Medicine, Greater Los Angeles Healthcare Service Veterans Affairs, Los Angeles, CA
Acne vulgaris is the most common skin disorder affecting millions of people worldwide and it is
widely accepted that inflammation as a result of immune responses targeting P. acnes play a sig-
nificant role in its pathogenesis. Our earlier studies have demonstrated a role for innate immune
response as P. acnes activates Toll like receptor 2 on monocytes to secrete inflammatory cytokines.
P. acnes has also been shown to trigger adaptive immune responses, leading to recruitment of acti-
vated Th1 cells to sites of early inflamed acne lesions. The role of recently defined subset of T cells,
Th17 cells, in acne is yet to be elucidated. Here, we investigate whether Th17 cells are involved in
the inflammatory response associated with P. acnes. We demonstrate here that P. acnes is a potent
inducer of IL-17 in human peripheral blood mononuclear cells (PBMCs). P. acnes treatment also
stimulated the production of IFN-γ but not IL-4. The activation of PBMCs with P. acnes induced a
strong mRNA expression of genes known to directly signal Th17 response including IL-17A, RORα,
RORγT, IL-17RA and IL-17RC. To determine which cytokines were responsible for stimulating P.
acnes induced Th17 cells, we incubated PBMCs with neutralizing antibodies to IL-17, IL-6, TGF-β,
IL-23p19, IL-4 and IFN-γ prior to treatment with P. acnes then measured IL-17 and Th17 cells. IL-6
and TGF-β neutralizing antibodies either alone or in combination led to a blockade of IL-17 pro-
duction by up to 95%. Neutralizing antibodies to IFN-γ and IL-4 increased IL-17 expression. We
also obtained acne biopsies and looked for IL-17 by immunohistochemical staining. We found that
IL-17 expressing cells were present in acne patients while none were detectable in skin biopsies
from healthy donors. Our in vivo data supports our in vitro data and suggest that IL-17 may play a
role in acne pathogenesis.
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